Pharmaceutical compositions of PD-1 antibodies and uses thereof

Abstract

The present disclosure provides pharmaceutical compositions comprising a human PD-1 ("hPD-1") antibody ("retifanlimab") and a buffer for storage and administration. The present disclosure further provides containers and kits comprising the pharmaceutical compositions. The present invention further provides uses of the pharmaceutical compositions, containers, and kits containing retifanlimab in the treatment of cancer, and in certain aspects, in the treatment of cancers that express PD-L1.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Patent Application No. 63 / 220006 (filed July 9, 2021; pending), which is incorporated by reference in its entirety into this application.

[0002] Sequence Listing Reference This application contains one or more sequence listings in accordance with 37 CFR §1.821 et seq., which sequence listings are disclosed herein.

[0003] The present disclosure provides pharmaceutical compositions comprising an anti-human PD-1 ("hPD-1") antibody ("retifanlimab") and a buffer for storage and administration. The present disclosure further provides containers and kits comprising the pharmaceutical compositions. The present invention further provides uses of the pharmaceutical compositions, containers, and kits containing retifanlimab for the treatment of cancer, and in certain embodiments, for the treatment of cancers that express PD-L1. [Background technology]

[0004] Programmed cell death-1 (also known as "PD-1", "CD279") is an immune checkpoint protein expressed on the surface of activated T cells, B cells, and monocytes. PD-1 mediates its inhibition of the immune system by binding to transmembrane protein ligands: Programmed cell death-ligand 1 (also known as "PD-L1", "B7-H1") and Programmed cell death-ligand 2 (also known as "PD-L2", "B7-DC"). Under normal circumstances, immune checkpoint proteins serve as targets of action to inhibit overactivation of T cells, thus preventing autoimmune damage. However, when the ligand is expressed by tumor cells, binding to the ligand serves to prevent immune system cells from accessing the tumor, thus compromising the immune system's ability to recognize and destroy tumor cells. Thus, overexpression of PD-L1 on tumor cells is often associated with a poor prognosis. The role of PD-1-ligand interactions in inhibiting T cell activation and proliferation suggests that these biomolecules may serve as therapeutic targets for the treatment of inflammation and cancer. Thus, the use of antibodies against PD-1 and its ligands, particularly PD-L1, has been proposed to treat infections and tumors, and to upregulate adaptive immune responses. Antibodies capable of specifically binding to PD-1 and PD-L1 have been reported. Summary of the Invention [Problem to be solved by the invention]

[0005] However, there remains an unmet need for the development of antibody compositions for patients with tumors that express PD-L1, including patients with tumors that express low levels of PD-L1 or who have failed other PD-1 therapies. The present disclosure directly addresses this and other needs, as described below. [Means for solving the problem]

[0006] In one embodiment, the disclosure provides a pharmaceutical composition comprising an anti-human PD-1 (hPD-1) antibody ("retifanlimab") and a buffer for storage and administration. The disclosure further provides containers and kits comprising the pharmaceutical composition. The disclosure further provides uses of the pharmaceutical compositions, containers, and kits containing retifanlimab, e.g., for treating cancer with a therapeutically or prophylactically effective amount of retifanlimab, and in certain embodiments, for treating cancers that express PD-L1.

[0007] In one embodiment, the disclosure provides a pharmaceutical composition comprising retifanlimab, acetate, sucrose, polysorbate 80 ("PS80"), and water. In certain embodiments, the disclosure provides an embodiment of the aforementioned pharmaceutical composition, wherein the acetate is present at a concentration of about 5 mM to about 30 mM. The disclosure further provides an embodiment of the aforementioned pharmaceutical composition, wherein the acetate comprises sodium acetate, or wherein the acetate comprises glacial acetic acid and sodium acetate.

[0008] The present disclosure further relates to a composition comprising: a) about 5 mM to about 30 mM acetate, about 50 mg / mL to about 130 mg / mL sucrose, about 0.02 mg / mL to about 0.6 mg / mL PS80, and water, wherein the pH of the composition is about 4.0 to about 6.5; or b) about 7.5 mM to about 20 mM acetate, about 50 mg / mL to about 130 mg / mL sucrose, about 0.05 mg / mL to about 0.6 mg / mL PS80, and water, wherein the pH of the composition is about 4.0 to about 6.5; or c) about 9 mM to about 11 mM acetate, about 76 mg / mL to about 104 mg / mL sucrose, about 0.08 mg / mL to about 0.53 mg / mL PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7; or d) Provided is an embodiment of the pharmaceutical composition described above, comprising about 9 mM to about 11 mM acetate, about 80 mg / mL to about 100 mg / mL sucrose, about 0.08 mg / mL to about 0.15 mg / mL PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7.

[0009] The present disclosure provides an embodiment of the above-mentioned pharmaceutical composition, wherein retifanlimab is present at a concentration of about 10 mg / mL to about 100 mg / mL. The present disclosure further provides an embodiment of the above-mentioned pharmaceutical composition, wherein retifanlimab is present at a concentration of about 20 mg / mL to about 30 mg / mL. The present disclosure further provides an embodiment of the above-mentioned pharmaceutical composition, wherein retifanlimab is present at a concentration of about 25 mg / mL.

[0010] The present disclosure provides an embodiment of the above-described pharmaceutical composition, wherein the acetate comprises glacial acetic acid at a concentration of about 0.05 mg / mL to about 0.35 mg / mL and sodium acetate trihydrate at a concentration of about 0.80 mg / mL to about 2.0 mg / mL.The present disclosure further provides an embodiment of the above-described pharmaceutical composition, wherein the acetate comprises glacial acetic acid at a concentration of about 0.18 mg / mL and sodium acetate trihydrate at a concentration of about 0.95 mg / mL.

[0011] The present disclosure provides an embodiment of the above pharmaceutical composition, wherein the sucrose is present in a concentration of about 80 mg / mL to about 100 mg / mL.The present disclosure further provides an embodiment of the above pharmaceutical composition, wherein the sucrose is present in a concentration of about 90 mg / mL.

[0012] The present disclosure provides an embodiment of the aforementioned pharmaceutical composition, wherein the PS80 is present at a concentration of about 0.08 mg / mL to about 0.15 mg / mL.The present disclosure further provides an embodiment of the aforementioned pharmaceutical composition, wherein the concentration of the PS80 is about 0.1 mg / mL.

[0013] The present disclosure provides an embodiment of the above pharmaceutical composition, wherein the pH of the composition is about 4.5 to about 5.7.The present disclosure further provides an embodiment of the above pharmaceutical composition, wherein the pH of the composition is about 5.1.

[0014] The present disclosure provides an embodiment of the aforementioned pharmaceutical composition, wherein the composition comprises about 25 mg / mL retifanlimab, about 0.18 mg / mL glacial acetic acid, about 0.95 mg / mL sodium acetate trihydrate, about 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is about 4.8 to about 5.4.

[0015] The present disclosure provides an embodiment of the pharmaceutical composition described above, wherein the composition has a shelf life of at least about 18 months at about 2°C to about 8°C. The present disclosure further provides an embodiment of the pharmaceutical composition described above, wherein the composition has a shelf life of about 24 months at about 2°C to about 8°C. The present disclosure further provides an embodiment of the pharmaceutical composition described above, wherein the composition has a shelf life of about 36 months at about 2°C to about 8°C. The present disclosure further provides an embodiment of the pharmaceutical composition described above, wherein the composition has a shelf life of about 48 months at about 2°C to about 8°C. The present disclosure further provides an embodiment of the pharmaceutical composition described above, wherein the composition has a shelf life of about 60 months at about 2°C to about 8°C.

[0016] The present disclosure provides an embodiment of the pharmaceutical composition described above, wherein the osmolality of the composition is about 200 to about 400 mOsm / kg·H2O. The present disclosure further provides an embodiment of the pharmaceutical composition described above, wherein the osmolality of the composition is about 225 to about 400 mOsm / kg·H2O. The present disclosure further provides an embodiment of the pharmaceutical composition described above, wherein the osmolality of the composition is about 250 to about 375 mOsm / kg·H2O. The present disclosure further provides an embodiment of the pharmaceutical composition described above, wherein the osmolality of the composition is about 260 to about 340 mOsm / kg·H2O.

[0017] The present disclosure provides an embodiment of the pharmaceutical composition described above, wherein the composition maintains the monomeric purity of the retifanlimab for at least about 3 months at about 25° C. The present disclosure further provides an embodiment of the pharmaceutical composition described above, wherein the composition maintains the monomeric purity of the retifanlimab for at least about 18 months at about 2° C. to about 8° C.

[0018] The present disclosure provides an embodiment of the pharmaceutical composition described above, wherein the composition maintains the heterogeneity profile of the retifanlimab for at least about 3 months at 25° C. The present disclosure further provides an embodiment of the pharmaceutical composition described above, wherein the composition maintains the heterogeneity profile of the retifanlimab for at least about 18 months at about 2° C. to about 8° C.

[0019] The disclosure further provides embodiments of any of the pharmaceutical compositions disclosed herein, wherein the water is sterile, non-pyrogenic, distilled water.

[0020] The present disclosure further provides embodiments of any of the pharmaceutical compositions disclosed herein, wherein said pharmaceutical composition is sterile.

[0021] The present disclosure further provides a container comprising any of the pharmaceutical compositions disclosed herein, wherein said container comprises about 10 mL volume, about 15 mL volume, or about 20 mL volume of said pharmaceutical composition.

[0022] The present disclosure further provides embodiments of the above-described pharmaceutical compositions, wherein said pharmaceutical composition does not contain an antioxidant.

[0023] The disclosure provides embodiments of the container, wherein the pharmaceutical composition of about 10 mL volume comprises: (a) about 250 mg of retifanlimab; (b) about 1.8 mg of glacial acetic acid; (c) about 9.5 mg of sodium acetate trihydrate; (d) about 900 mg of sucrose; (e) about 1 mg of PS80; and (f) water; and the pH of the composition is about 4.8 to about 5.4.

[0024] The disclosure further provides embodiments of the container, wherein the pharmaceutical composition of about 15 mL volume comprises: (a) about 375 mg of retifanlimab; (b) about 2.7 mg of glacial acetic acid; (c) about 14.25 mg of sodium acetate trihydrate; (d) about 1350 mg of sucrose; (e) about 1.5 mg of PS80; and (f) water; and the pH of the composition is about 4.8 to about 5.4.

[0025] The present disclosure further provides an embodiment of the container, wherein the pharmaceutical composition having a volume of about 20 mL comprises: (a) about 500 mg of retifanlimab; (b) about 3.6 mg of glacial acetic acid; (c) about 19 mg of sodium acetate trihydrate; (d) about 1800 mg of sucrose; (e) about 2 mg of PS80; and (f) water; and the pH of the composition is about 4.8 to about 5.4.

[0026] The present disclosure further provides a kit comprising any of the pharmaceutical compositions disclosed herein, or any of the containers disclosed herein, and optionally, instructions for administering the pharmaceutical composition to a subject in need thereof.

[0027] The present disclosure further provides a container comprising a pharmaceutical composition, the composition comprising: a) about 21 mg / mL to about 29 mg / mL of retifanlimab, about 0.16 mg / mL to about 0.20 mg / mL of glacial acetic acid, about 0.86 mg / mL to about 1.1 mg / mL of sodium acetate trihydrate, about 76 mg / mL to about 104 mg / mL of sucrose, about 0.08 mg / mL to about 0.53 mg / mL of PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7; or b) about 22.5 mg / mL to about 27.5 mg / mL of retifanlimab, about 0.16 mg / mL to about 0.20 mg / mL of glacial acetic acid, about 0.86 mg / mL to about 1.1 mg / mL of sodium acetate trihydrate, about 76 mg / mL to about 104 mg / mL of sucrose, about 0.08 mg / mL to about 0.53 mg / mL of PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7; or c) about 250 mg of retifanlimab, about 1.8 mg of glacial acetic acid, about 9.5 mg of sodium acetate trihydrate, about 900 mg of sucrose, and about 1 mg of PS80, wherein the pH of the composition is about 4.8 to about 5.4; or d) about 375 mg of retifanlimab, about 2.7 mg of glacial acetic acid, about 14.25 mg of sodium acetate trihydrate, about 1350 mg of sucrose, and about 1.5 mg of PS80, wherein the pH of the composition is about 4.8 to about 5.4; or e) a container comprising about 500 mg of retifanlimab, about 3.6 mg of glacial acetic acid, about 19 mg of sodium acetate trihydrate, about 1800 mg of sucrose, and about 2 mg of PS80, wherein the pH of the composition is about 4.8 to about 5.4; Optionally, instructions for administering said pharmaceutical composition to a subject in need thereof. A kit is provided, comprising:

[0028] The present disclosure provides an embodiment of the above-mentioned kit, wherein the composition comprises about 25 mg / mL retifanlimab, about 0.18 mg / mL glacial acetic acid, about 0.95 mg / mL sodium acetate trihydrate, about 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is about 4.8 to about 5.4.

[0029] The present disclosure provides an embodiment of the above kit, wherein the composition comprises about 250 mg of retifanlimab, about 1.8 mg of glacial acetic acid, about 9.5 mg of sodium acetate trihydrate, about 900 mg of sucrose, about 1 mg of PS 80, and the pH of the composition is about 4.8 to about 5.4. The present disclosure further provides an embodiment of the above kit, wherein the composition comprises about 375 mg of retifanlimab, about 2.7 mg of glacial acetic acid, about 14.25 mg of sodium acetate trihydrate, about 1350 mg of sucrose, about 1.5 mg of PS 80, and the pH of the composition is about 4.8 to about 5.4.

[0030] The present disclosure provides an embodiment of the above-mentioned kit, wherein the composition comprises about 500 mg of retifanlimab, about 3.6 mg of glacial acetic acid, about 19 mg of sodium acetate trihydrate, about 1800 mg of sucrose, about 2 mg of PS80, and the pH of the composition is about 4.8 to about 5.4.

[0031] The present disclosure further provides a sealed package containing any of the pharmaceutical compositions disclosed herein, any of the containers disclosed herein, or any of the kits disclosed herein, and optionally further containing instructions for administering the pharmaceutical composition to a subject in need thereof.

[0032] The present disclosure further provides a method of treating cancer comprising administering retifanlimab to a subject in need thereof using any of the pharmaceutical compositions disclosed herein, any of the containers disclosed herein, any of the kits disclosed herein, or any of the sealed packages disclosed herein.

[0033] The present disclosure further provides a method of treating cancer comprising administering retifanlimab to a subject in need thereof using any of the pharmaceutical compositions disclosed herein, any of the containers disclosed herein, any of the sealed packages disclosed herein, or any of the kits disclosed herein, the method comprising: a) diluting the pharmaceutical composition in a container in 0.9% sodium chloride or in 5% dextrose in water (D5W) to obtain a dosing solution; b) inverting the container to mix the diluted solution; and c) attaching the container containing the dosing solution to a device for administration to the subject. Includes.

[0034] The present disclosure also provides the use of any of the pharmaceutical compositions disclosed herein, any of the containers disclosed herein, any of the sealed packages disclosed herein, or any of the kits disclosed herein, for the treatment of cancer in a subject in need thereof.

[0035] The disclosure further provides a use of any of the pharmaceutical compositions disclosed herein, any of the containers disclosed herein, any of the sealed packages disclosed herein, or any of the kits disclosed herein, for the treatment of cancer in a subject in need thereof, said use comprising: a) diluting the pharmaceutical composition in a container in 0.9% sodium chloride or in 5% dextrose in water (D5W) to obtain a dosing solution; b) inverting the container to mix the diluted solution; and c) attaching the container containing the dosing solution to a device for administration to the subject. Includes.

[0036] The present disclosure further provides an embodiment of the above method or use, wherein the container is an IV bag containing 0.9% sodium chloride.The present disclosure further provides an embodiment of the above use, wherein the container is an IV bag containing D5W.

[0037] The present disclosure provides embodiments of any of the methods disclosed herein or any of the uses disclosed herein, wherein the dosing solution maintains the monomeric purity of the retifanlimab for about 6 hours at 25° C. or for about 24 hours at about 2° C. to about 8° C.

[0038] The present disclosure provides an embodiment of any of the methods disclosed herein or any of the uses disclosed herein, wherein said administering is by IV infusion over at least 30 minutes.The present disclosure further provides an embodiment of any of the methods disclosed herein or any of the uses disclosed herein, wherein said administering is by IV infusion over at least 60 minutes.

[0039] The present disclosure provides an embodiment of any of the methods disclosed herein or any of the uses disclosed herein, wherein the pharmaceutical composition is diluted to obtain a flat dose of about 375 mg.The present disclosure further provides an embodiment of any of the methods disclosed herein or any of the uses disclosed herein, wherein the pharmaceutical composition is diluted to obtain a flat dose of about 500 mg.

[0040] The present disclosure provides embodiments of any of the methods disclosed herein or any of the uses disclosed herein, wherein said administration of the dosing solution is once every two weeks, once every three weeks, or once every four weeks.

[0041] The present disclosure provides an embodiment of any of the methods disclosed herein or any of the uses disclosed herein, wherein the cancer expresses PD-L1.

[0042] The present disclosure relates to cancers including: adrenal cancer, AIDS-related cancer, alveolar soft part sarcoma, anal cancer, squamous cell carcinoma of the anal canal (SCAC), bladder cancer, bone cancer, brain and spinal cancer, breast cancer, HER2 +Breast cancer or triple-negative breast cancer (TNBC), carotid body tumor, cervical cancer, HPV-associated cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, desmoplastic small round cell tumor, ependymoma, endometrial cancer, unselected endometrial cancer, MSI-high endometrial cancer, dMMR endometrial cancer, DNA polymerase epsilon (POLE) exonuclease domain mutation-positive endometrial cancer, Ewing's sarcoma, extraskeletal myxoid chondrosarcoma, gallbladder or bile duct cancer, cholangiocarcinoma, gastric cancer cancer), esophagogastric junction (GEJ) cancer, gestational trophoblastic disease, germ cell tumors, glioma, glioblastoma, head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), hematological malignancies, hepatocellular carcinoma, islet cell tumors, Kaposi's sarcoma, kidney cancer, renal cell carcinoma (RCC), clear cell RRC, papillary RCC, and chromophobe RCC, leukemia, acute myeloid leukemia, liposarcoma / malignant lipomatous tumor, liver cancer, hepatocellular carcinoma (HCC), lymphoma, diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), lung cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSLC), In one embodiment, the cancer is selected from the group consisting of melanoma, ovarian cancer, pancreatic cancer, papillary thyroid cancer, parathyroid tumor, pediatric cancer, peripheral nerve sheath tumor, pharyngeal cancer, pheochromocytoma, pituitary tumor, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), posterior uveal melanoma, renal metastasis cancer, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin cancer, Merkel cell carcinoma, small round blue cell tumor of childhood, neuroblastoma, rhabdomyosarcoma, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid cancer, urothelial carcinoma, and uterine cancer.

[0043] The present disclosure provides an embodiment of any of the methods disclosed herein or any of the uses disclosed herein, wherein the cancer is anal cancer, breast cancer, colorectal cancer, endometrial cancer, gastric cancer, GEJ cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and urothelial cancer. The present disclosure further provides an embodiment of any of the methods disclosed herein or any of the uses disclosed herein, wherein the cancer is SCAC, NSCLC, MSI-high endometrial cancer, dMMR endometrial cancer, POLE exonuclease domain mutation positive endometrial cancer, melanoma, Merkel cell carcinoma, SCCHN, mCRPC, RCC, clear cell RCC, or urothelial cancer.

[0044] The present disclosure further provides an embodiment of any of the methods disclosed herein or any of the uses disclosed herein, wherein the subject is a human subject.

[0045] The above summary of the invention and the following description of the drawings and detailed description are for the purposes of illustration and description. They are intended to provide further details of the present disclosure and should not be construed as limiting. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the present disclosure. [Brief description of the drawings]

[0046] [Figure 1] Figure 1 shows the predicted profiler for a formulation stored at 5 ± 3 °C for 6 months (2–8 °C 6M). High molecular weight species (HMWS), monomer, acidic variant (AV), main charge peak (MP), basic variant (BV), and subvisible particles (≥ 10 μm and ≥ 25 μm) (rows) are plotted against changes in sucrose concentration, pH, PS-80 concentration, retifanlimab concentration, and ionic strength (columns). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0047] The present disclosure provides pharmaceutical compositions comprising a human PD-1 (hPD-1) antibody ("retifanlimab") and a buffer for storage and administration. The present disclosure further provides containers and kits comprising the pharmaceutical compositions. The present disclosure further provides uses of the above-described pharmaceutical compositions, containers, and kits containing retifanlimab, e.g., for treating cancer with a therapeutically or prophylactically effective amount of retifanlimab, and in certain embodiments, for treating cancers that express PD-L1.

[0048] Retifanlimab (also known as MGA012 and INCMGA00012; CAS Registry Number 2079108-44-2) is a humanized hinge-stabilized IgG4 kappa monoclonal antibody that recognizes and binds to human PD-1 expressed by T and B lymphocytes. Retifanlimab contains a human IgG4 Fc region that contains a serine to proline mutation (S228P) in the hinge region to reduce or eliminate hinge interchain disulfide instability, where the numbering of the residues in the IgG heavy chain is that of the EU index in Kabat (Kabat, Sequences Of Proteins Of Immunological Interest (National Institutes of Health, Bethesda, Md., 1987 and 1991)) and refers to the numbering of human IgG4 EU antibodies. The amino acid sequences of the heavy and light chains of retifanlimab are presented below (WHO Drug Information 2019, Proposed INN: List 121, 33(2)): 326-327). The CDRs as defined by Kabat are underlined.

[0049] The amino acid sequence of the heavy chain of retifanlimab is (SEQ ID NO: 1) (CDR H Residues are shown in bold and underlined, constant regions are shown double underlined, and the S228P mutation is shown in bold and double underlined): JPEG2024525566000002.jpg45143

[0050] The amino acid sequence of the light chain of retifanlimab is (SEQ ID NO:2) (CDR L Residues are shown in bold and underlined, and constant regions are shown double underlined): JPEG2024525566000003.jpg26143

[0051] The pharmaceutical composition of the present disclosure comprises retifanlimab, a buffering agent, and a stabilizer, and is also referred to herein as a "retifanlimab composition."

[0052] As used herein, "about" will be understood by one of ordinary skill in the art and will vary to some extent depending on the context in which the phrase is used. If there are uses of the phrase that are not clear to a person of ordinary skill in the art and not otherwise defined herein, "about" will mean up to plus or minus 10% of the particular term, given the context in which the phrase is used.

[0053] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a" component includes embodiments having two or more of such components unless the context clearly dictates otherwise. Also, when the word "or" is used without a preceding "either" (or similar language indicating that "or" is clearly exclusive, such as "only one of x or y"), the word is intended to be interpreted as inclusive (e.g., "x or y" means one or both of x or y).

[0054] The term "and / or" is also to be construed as inclusive (e.g., "x and / or y" means one or both of x and y). When "and / or" or "or" is used as a conjunction with a group of more than two items, the group is to be construed as including only one item, all items, or any combination or number of items. Furthermore, as used in the specification and claims, the terms "have," "including," and "include" are to be construed as equivalent to the term "comprise." There may optionally be elements other than the elements specifically identified by the "and / or" clause, related or unrelated to the elements specifically identified above. As a non-limiting example, a reference to "X and / or Y" can refer in some embodiments to only X (optionally including elements other than Y); in some embodiments to only Y (optionally including elements other than X); and in some further embodiments to both X and Y (optionally including other elements).

[0055] As used herein, "acetate" refers to the acetate component of a pharmaceutical composition. For example, the acetate component can be composed of acetic acid, an acetate salt, and / or an acetate buffer.

[0056] As used herein, the term "aqueous" refers to a solution that contains water.

[0057] As used herein, the term "stable" refers to retifanlimab substantially retaining its physical stability, chemical stability, pharmaceutical activity, and / or its biological activity upon storage.

[0058] The term "shelf-life" refers to the period over which a pharmaceutical composition can be stored while substantially retaining its physical stability, chemical stability, pharmaceutical activity, and / or biological activity.

[0059] As will be understood by those skilled in the art, for all purposes, particularly in terms of providing a written description, all ranges disclosed herein include all possible subranges and combinations of subranges thereof, including the endpoints. Thus, all ranges disclosed are to be understood to include and provide support for the claims as set forth herein, any subranges or individual values ​​subsumed by each range. For example, if a range of 1 to 10 is described, this is to be understood to include and provide support for the claims as set forth herein, any subranges or individual values ​​between and including the minimum value of 1 and the maximum value of 10; i.e., any subrange beginning with a minimum value of 1 or more and ending with a maximum value of 10 or less (e.g., 5.5 to 10, 2.34 to 3.56, etc.), or any value between 1 and 10 (e.g., 3, 5.8, 9.9994, etc.).

[0060] Any range recited is readily recognizable as fully descriptive and allowing the range to be equally divided into at least 2, 3, 4, 5, 10, etc. As a non-limiting example, each range discussed herein can be readily divided into a lower third, a middle third, an upper third, etc. As will also be appreciated by those skilled in the art, all expressions such as "up to," "at least," "greater than," "less than" and the like refer to ranges that are inclusive of the recited numbers and that can be subsequently divided into subranges as discussed herein. Additionally, as will be appreciated by those skilled in the art, a range includes individual numbers. Thus, for example, a group having 1-3 layers refers to a group having 1, 2, or 3 layers. Similarly, a group having 1-5 layers refers to a group having 1, 2, 3, 4, or 5 layers.

[0061] The embodiments disclosed herein as exemplary may suitably be practiced in the absence of any element or elements, or any limitation, not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," etc., are to be understood in an open and non-limiting sense. Furthermore, the terms and expressions employed herein are used as terms of description, not of limitation, and the use of these terms and expressions is not intended to exclude any equivalents or portions of the features shown and described, recognizing that various modifications are possible within the scope of the claimed technology. Furthermore, the phrase "consisting essentially of" is to be understood as including the elements specifically described and additional elements that do not materially affect the basic and novel characteristics of the claimed technology. The phrase "consisting of" excludes any elements not specified.

[0062] Definitions contained in texts incorporated by reference are excluded to the extent that they conflict with definitions in this disclosure.

[0063] The present disclosure provides a pharmaceutical composition that substantially retains the physical and chemical stability of retifanlimab, as well as its pharmaceutical and / or biological activity, during storage. In one embodiment, about 90% or more, about 80% or more, about 70% or more, or about 60% or more of the physical stability, chemical stability, pharmaceutical activity and / or biological activity of retifanlimab is retained during storage of the pharmaceutical composition of the present disclosure. In one embodiment, about 90% or more, about 85% or more, about 80% or more, about 75% or more, about 70% or more, about 65% or more, or about 60% or more of the physical stability, chemical stability, pharmaceutical activity and / or biological activity of retifanlimab is retained during the shelf life. The shelf life of a pharmaceutical composition is generally selected based on the period during which the molecule is stable in the composition.

[0064] In one embodiment, the shelf life of the pharmaceutical composition of the present disclosure is at least about 1 month at about 25° C., at least about 2 months at about 25° C., at least about 3 months at about 25° C., at least about 4 months at about 25° C., at least about 6 months at about 25° C., or at least about 7, at least about 8, at least about 9, at least about 10, at least about 11, or at least about 12 months at about 25° C. In another embodiment, the shelf life of the pharmaceutical composition of the present disclosure is at least about 6 months, at least about 12 months, at least about 18 months, at least about 24 months, at least about 30 months, at least about 36 months, at least about 48 months, or at least about 60 months, all at about 2° C. to about 8° C. In one embodiment, the shelf life of the pharmaceutical composition of the present disclosure is at least about 6 months at about 25° C. In another embodiment, the shelf life of the pharmaceutical composition of the present disclosure is at least about 24 months at about 2° C. to about 8° C. In another embodiment, the shelf life of the pharmaceutical composition of the present disclosure is at least about 36 months at about 2° C. to about 8° C. In another embodiment, the shelf life of the pharmaceutical composition of the present disclosure is at least about 48 months at about 2° C. to about 8° C. In another embodiment, the shelf life of the pharmaceutical composition of the present disclosure is at least about 60 months at about 2° C. to about 8° C.

[0065] One measure of physical and chemical stability is the monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosage solution of the present disclosure. The monomeric purity of retifanlimab can be determined by assessing the amount of protein having the expected molecular weight (monomeric retifanlimab), species having a molecular weight higher than monomer (HMW), and / or species having a molecular weight lower than monomer (LMW) in such a composition or solution by any suitable method. Thus, the loss of monomeric purity can be measured by determining the loss of protein having the expected molecular weight (monomer) and / or the accumulation of HMW and / or LMW species after a designated period of time. In certain embodiments, the percentage (%) of each species (monomer, HMW, and LMW) is calculated as a percentage (%) of the total protein. In one embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is about 15% or less, or about 10% or less, or about 5% or less, or about 4% or less, or about 3% or less, or about 2% or less, or about 1% or less over the indicated period. In one embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is about 5% or less over the indicated period. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is less than about 4% over the indicated period. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is about 3% or less over the indicated period. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is about 2% or less over the indicated time period. In certain embodiments, the amount of monomeric, HMW and / or LMW species of retifanlimab in the composition of the present disclosure or in the dosing solution of the present disclosure is measured by size exclusion high performance liquid chromatography (SE-HPLC).In such embodiments, the percentages of each species are calculated as the area of ​​the SE-HPLC species peaks (i.e., monomeric, HMW, LMW) divided by the sum of all peaks, i.e., the percentage of total protein.

[0066] In other embodiments, the monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for at least about 1 month at about 25° C., at least about 2 months at about 25° C., at least about 3 months at about 25° C., at least about 4 months at about 25° C., at least about 6 months at about 25° C., at least about 6 months at about 2° C. to about 8° C., at least about 12 months at about 2° C. to about 8° C., at least about 18 months at about 2° C. to about 8° C., at least about 24 months at about 2° C. to about 8° C., at least about 30 months at about 2° C. to about 8° C., at least about 36 months at about 2° C. to about 8° C., at least about 48 months, at least about 60 months, or more than about 60 months at about 2° C. to about 8° C. In one embodiment, the monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for at least about 6 months at about 25° C. In another embodiment, the monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for about 36 months or more at about 2° C. to about 8° C. In another embodiment, the monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for about 48 months at about 2° C. to about 8° C. In another embodiment, the monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for about 60 months at about 2° C. to about 8° C.

[0067] Another measure of stability is the stability of the charge heterogeneity profile of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosage solution of the present disclosure. The protein composition may contain various variants with different isoelectric points (pI). Such variants are called charge variants. Thus, the heterogeneity profile can be determined by measuring the main charge peak (MCP), acidic variant (AV), and basic variant (BV) by any suitable method. For example, the retifanlimab composition of the present disclosure can contain MCP, AV, and BV components, and the change in the heterogeneity profile can be measured by determining the loss of MCP and / or the accumulation of AV and / or BV after the indicated time. In one embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is about 15% or less, or about 10% or less, or about 5% or less, or about 4% or less, or about 3% or less, or about 2% or less, or about 1% or less over the indicated period. In one embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is about 15% or less, or about 10% or less, or about 5% or less, or about 4% or less, or about 3% or less, or about 2% or less, or about 1% or less over the indicated period. In another embodiment, the increase in BV of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is about 15% or less, or about 10% or less, or about 5% or less, or about 4% or less, or about 3% or less, or about 2% or less, or about 1% or less over the indicated period. In another embodiment, the MCP of retifanlimab in the pharmaceutical composition or dosing solution of the present disclosure is reduced by about 7% or less over the indicated period. In another embodiment, the MCP of retifanlimab in the pharmaceutical composition or dosing solution of the present disclosure is reduced by about 6% or less over the indicated period. In another embodiment, the MCP of retifanlimab in the pharmaceutical composition or dosing solution of the present disclosure is reduced by about 5% or less over the indicated period.In another embodiment, the AV of retifanlimab in the pharmaceutical composition or dosing solution of the present disclosure increases by about 7% or less over the indicated period. In another embodiment, the AV of retifanlimab in the pharmaceutical composition or dosing solution of the present disclosure increases by about 6% or less over the indicated period. In another embodiment, the AV of retifanlimab in the pharmaceutical composition or dosing solution of the present disclosure increases by about 5% or less over the indicated period. In another embodiment, the BV of retifanlimab in the pharmaceutical composition or dosing solution of the present disclosure increases by about 4% or less over the indicated period. In another embodiment, the BV of retifanlimab in the pharmaceutical composition or dosing solution of the present disclosure increases by about 3% or less over the indicated period. In another embodiment, the BV of retifanlimab in the pharmaceutical composition or dosing solution of the present disclosure increases by about 2% or less over the indicated period. In certain embodiments, the MCP, AV, and BV of retifanlimab in a pharmaceutical composition of the disclosure or a dosing solution of the disclosure are measured by capillary isoelectric focusing (cIEF).

[0068] In other embodiments, the heterogeneity profile of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for at least about 1 month at about 25° C., at least about 2 months at about 25° C., at least about 3 months at about 25° C., at least about 4 months at about 25° C., at least about 6 months at about 25° C., at least about 6 months at about 2° C. to about 8° C., at least about 12 months at about 2° C. to about 8° C., at least about 18 months at about 2° C. to about 8° C., at least about 24 months at about 2° C. to about 8° C., at least about 30 months at about 2° C. to about 8° C., at least about 36 months at about 2° C. to about 8° C., at least about 48 months, at least about 60 months, or more than about 60 months at about 2° C. to about 8° C. In one embodiment, the heterogeneity profile of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for at least about 6 months at about 25° C. In another embodiment, the heterogeneity profile of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for about 36 months or more at about 2° C. to about 8° C. In another embodiment, the heterogeneity profile of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for about 48 months at about 2° C. to about 8° C. In another embodiment, the heterogeneity profile of retifanlimab in the pharmaceutical composition of the present disclosure is maintained for about 60 months at about 2° C. to about 8° C.

[0069] The components of the pharmaceutical composition (i.e., retifanlimab composition) of the present disclosure can be supplied mixed in unit dosage form, e.g., as a liquid composition in an airtight container such as a vial, ampoule, or sachet indicating the quantity of active agent. In one embodiment, the pharmaceutical composition of the present disclosure is supplied as a liquid solution. Such liquid solutions can be stored in the original container at about 2°C to about 8°C until ready for administration, although such liquid solutions can also be stored at room temperature (about 25°C) for short periods of time prior to administration.

[0070] In certain embodiments where the retifanlimab compositions of the present disclosure are administered by injection, the compositions can be dispensed using, for example, a container, bag, or infusion bottle containing sterile 0.9% sodium chloride (e.g., saline). In certain embodiments where the retifanlimab compositions of the present disclosure are administered by injection, 0.9% sodium chloride can be provided so that the ingredients can be mixed prior to administration as detailed herein. Such retifanlimab compositions can include a prophylactically or therapeutically effective amount of retifanlimab.

[0071] In certain embodiments in which the retifanlimab compositions of the present disclosure are administered by injection, the compositions can be dispensed using a container, bag, or infusion bottle containing sterile 5% dextrose in water ("D5W"). In certain embodiments in which the retifanlimab compositions of the present disclosure are administered by injection, D5W can be provided to allow the ingredients to be mixed prior to administration as detailed herein. Such retifanlimab compositions can include a prophylactically or therapeutically effective amount of retifanlimab.

[0072] In one embodiment, the pharmaceutical composition of the present disclosure comprises retifanlimab, acetate, sucrose, PS80, and water. In certain embodiments, the pharmaceutical composition of the present disclosure does not comprise an antioxidant.

[0073] The acetate component can be comprised of acetic acid and acetate salts. Acceptable acetate salts include, but are not limited to: calcium acetate, magnesium acetate, potassium acetate, sodium acetate, and zinc acetate. In one embodiment, the acetate salts include glacial acetic acid and sodium acetate.

[0074] In one embodiment, the pharmaceutical composition of the present disclosure contains retifanlimab at a concentration of about 10 mg / mL to about 100 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure contains retifanlimab at a concentration of about 20 mg / mL to about 30 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure contains retifanlimab at a concentration of about 22.5 mg / mL to about 27.5 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure contains retifanlimab at a concentration of about 25 mg / mL. Concentrations between any of these values ​​are also contemplated, for example, about 15 mg / mL, about 18 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, about 80 mg / mL, etc.

[0075] In one embodiment, the pharmaceutical composition of the present disclosure comprises about 5 mM to about 30 mM acetate. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 5 mM to about 25 mM acetate. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 7.5 mM to about 20 mM acetate. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 7.5 mM to about 15 mM acetate. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 9 mM to about 11 mM acetate. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 10 mM acetate. Concentrations between any of these values ​​are also contemplated, for example, about 8 mM, about 14 mM, about 18 mM, etc. In one embodiment, the acetate in the composition of the present disclosure comprises glacial acetic acid and sodium acetate (e.g., sodium acetate anhydrous, sodium acetate monohydrate, and / or sodium acetate trihydrate). It will be appreciated that the desired acetate concentration can be achieved by using sodium acetate monohydrate and / or sodium acetate anhydrous and / or sodium acetate trihydrate in combination with glacial acetic acid. As provided herein, other forms of acetate, including but not limited to magnesium acetate, potassium acetate, calcium acetate, and zinc acetate, can be used in place of sodium acetate in the acetate buffer.

[0076] In one embodiment, the pharmaceutical composition of the present disclosure comprises glacial acetic acid at a concentration of about 0.05 mg / mL to about 0.35 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises glacial acetic acid at a concentration of about 0.1 mg / mL to about 0.3 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises glacial acetic acid at a concentration of about 0.16 mg / mL to about 0.20 mg / mL. In yet another embodiment, the pharmaceutical composition of the present disclosure comprises glacial acetic acid at a concentration of about 0.18 mg / mL. Concentrations between any of these values ​​are also contemplated, such as about 0.08 mg / mL, 0.15 mg / mL, 0.25 mg / mL, etc.

[0077] In one embodiment, the pharmaceutical composition of the present disclosure comprises sodium acetate trihydrate at a concentration of about 0.8 mg / mL to about 2.0 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises sodium acetate trihydrate at a concentration of about 0.8 mg / mL to about 1.3 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises sodium acetate trihydrate at a concentration of about 0.86 mg / mL to about 1.1 mg / mL. In yet another embodiment, the pharmaceutical composition of the present disclosure comprises sodium acetate trihydrate at a concentration of about 0.95 mg / mL. Concentrations between any of these values ​​are also contemplated, such as about 0.9 mg / mL, about 1.2 mg / mL, about 1.7 mg / mL, etc.

[0078] In one embodiment, the pharmaceutical composition of the present disclosure comprises glacial acetic acid at a concentration of about 0.05 mg / mL to about 0.35 mg / mL and sodium acetate trihydrate at a concentration of about 0.5 mg / mL to about 2.0 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises glacial acetic acid at a concentration of about 0.1 mg / mL to about 0.3 mg / mL and sodium acetate trihydrate at a concentration of about 0.8 mg / mL to about 1.3 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises glacial acetic acid at a concentration of about 0.16 mg / mL to about 0.20 mg / mL and sodium acetate trihydrate at a concentration of about 0.86 mg / mL to about 1.1 mg / mL. In yet another embodiment, the pharmaceutical composition of the present disclosure comprises glacial acetic acid at a concentration of about 0.18 mg / mL and sodium acetate trihydrate at a concentration of about 0.95 mg / mL.

[0079] In one embodiment, the pharmaceutical composition of the present disclosure comprises sucrose at a concentration of about 50 mg / mL to about 130 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises sucrose at a concentration of about 76 mg / mL to about 104 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises sucrose at a concentration of about 80 mg / mL to about 100 mg / mL. In yet another embodiment, the pharmaceutical composition of the present disclosure comprises sucrose at a concentration of about 90 mg / mL. Concentrations between any of these values ​​are also contemplated, such as about 85 mg / mL, about 87 mg / mL, about 92 mg / mL, etc.

[0080] In one embodiment, the pharmaceutical composition of the present disclosure comprises a PS80 concentration of about 0.02 mg / mL to about 0.6 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises a PS80 concentration of about 0.05 mg / mL to about 0.6 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises a PS80 concentration of about 0.08 mg / mL to about 0.53 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises a PS80 concentration of about 0.08 mg / mL to about 0.15 mg / mL. In another embodiment, the pharmaceutical composition of the present disclosure comprises a PS80 concentration of about 0.1 mg / mL. Concentrations between any of these values ​​are also contemplated, such as about 0.09 mg / mL, about 0.11 mg / mL, about 0.13 mg / mL, etc.

[0081] In one embodiment, the pH of the pharmaceutical composition of the present disclosure is about 4.0 to about 6.5. In another embodiment, the pH of the pharmaceutical composition of the present disclosure is about 4.5 to about 5.7. In another embodiment, the pH of the pharmaceutical composition of the present disclosure is about 5.1. In another embodiment, the pH of the pharmaceutical composition of the present disclosure is about 4.8 to about 5.4 (i.e., about 5.1±0.3). pH values ​​between any of these values ​​are also contemplated, such as a pH of about 4.7, about 4.9, about 5.3, or about 5.5.

[0082] In one embodiment, the pharmaceutical composition of the present disclosure comprises about 10 mg / mL to about 100 mg / mL of retifanlimab, about 5 mM to about 30 mM of acetate, about 50 mg / mL to about 130 mg / mL of sucrose, about 0.02 mg / mL to about 0.6 mg / mL of PS80, and water, and the pH of the composition is about 4.0 to about 6.5. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 10 mg / mL to about 100 mg / mL of retifanlimab, about 7.5 mM to about 20 mM of acetate, about 50 mg / mL to about 130 mg / mL of sucrose, about 0.05 mg / mL to about 0.6 mg / mL of PS80, and water, and the pH of the composition is about 4.0 to about 6.5. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 20 mg / mL to about 30 mg / mL retifanlimab, about 9 mM to about 11 mM acetate, about 76 mg / mL to about 104 mg / mL sucrose, about 0.08 mg / mL to about 0.53 mg / mL PS80, and water, and the pH of the composition is about 4.5 to about 5.7. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 22.5 mg / mL to about 27.5 mg / mL retifanlimab, about 9 mM to about 11 mM acetate, about 80 mg / mL to about 100 mg / mL sucrose, about 0.08 mg / mL to about 0.15 mg / mL PS80, and water, and the pH of the composition is about 4.5 to about 5.7. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 25 mg / mL retifanlimab, about 10 mM acetate, 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is about 5.1. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 25 mg / mL retifanlimab, about 10 mM acetate, 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is about 4.8 to about 5.4.

[0083] In one embodiment, a pharmaceutical composition of the present disclosure comprises about 10 mg / mL to about 100 mg / mL of retifanlimab, about 0.05 mg / mL to about 0.35 mg / mL of glacial acetic acid, about 0.80 mg / mL to about 2.0 mg / mL of sodium acetate trihydrate, about 50 mg / mL to about 130 mg / mL of sucrose, about 0.02 mg / mL to about 0.6 mg / mL of PS80, and water, wherein the pH of the composition is about 4.0 to about 6.5. In another embodiment, a pharmaceutical composition of the present disclosure comprises about 10 mg / mL to about 100 mg / mL of retifanlimab, about 0.1 mg / mL to about 0.3 mg / mL of glacial acetic acid, about 0.80 mg / mL to about 2.0 mg / mL of sodium acetate trihydrate, about 50 mg / mL to about 130 mg / mL of sucrose, about 0.05 mg / mL to about 0.6 mg / mL of PS80, and water, wherein the pH of the composition is about 4.0 to about 6.5. In another embodiment, a pharmaceutical composition of the present disclosure comprises about 20 mg / mL to about 30 mg / mL retifanlimab, about 0.16 mg / mL to about 0.20 mg / mL glacial acetic acid, about 0.86 mg / mL to about 1.1 mg / mL sodium acetate trihydrate, about 76 mg / mL to about 104 mg / mL sucrose, about 0.08 mg / mL to about 0.53 mg / mL PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7. In one embodiment, a pharmaceutical composition of the present disclosure comprises about 22.5 mg / mL to about 27.5 mg / mL of retifanlimab, about 0.16 mg / mL to about 0.20 mg / mL of glacial acetic acid, about 0.86 mg / mL to about 1.1 mg / mL of sodium acetate trihydrate, 76 mg / mL to about 104 mg / mL of sucrose, about 0.08 mg / mL to about 0.53 mg / mL of PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7. In another embodiment, a pharmaceutical composition of the present disclosure comprises about 22.5 mg / mL to about 27.5 mg / mL of retifanlimab, about 0.16 mg / mL to about 0.20 mg / mL of glacial acetic acid, about 0.86 mg / mL to about 1.1 mg / mL of sodium acetate trihydrate, about 80 mg / mL to about 100 mg / mL of sucrose, about 0.08 mg / mL to about 0.15 mg / mL of PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7.In another embodiment, the pharmaceutical composition of the present disclosure comprises about 25 mg / mL retifanlimab, about 0.18 mg / mL glacial acetic acid, about 0.95 mg / mL sodium acetate trihydrate, about 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is about 5.1. In another embodiment, the pharmaceutical composition of the present disclosure comprises about 25 mg / mL retifanlimab, about 10 mM acetate, 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is about 4.8 to about 5.4.

[0084] In one embodiment, about 10 mL of the pharmaceutical composition of the present disclosure comprises about 250 mg of retifanlimab, about 1.8 mg of glacial acetic acid, about 9.5 mg of sodium acetate trihydrate, about 900 mg of sucrose, about 1 mg of PS80, and water, and the pH of the composition is about 5.1. In another embodiment, about 10 mL of the pharmaceutical composition of the present disclosure comprises about 250 mg of retifanlimab, about 1.8 mg of glacial acetic acid, about 9.5 mg of sodium acetate trihydrate, about 900 mg of sucrose, about 1 mg of PS80, and water, and the pH of the composition is about 4.8 to about 5.4.

[0085] In another embodiment, about 15 mL of the pharmaceutical composition of the present disclosure comprises about 375 mg of retifanlimab, about 2.7 mg of glacial acetic acid, about 14.25 mg of sodium acetate trihydrate, about 1350 mg of sucrose, about 1.5 mg of PS80, and water, and the pH of the composition is about 5.1. In another embodiment, about 15 mL of the pharmaceutical composition of the present disclosure comprises about 375 mg of retifanlimab, about 2.7 mg of glacial acetic acid, about 14.25 mg of sodium acetate trihydrate, about 1350 mg of sucrose, about 1.5 mg of PS80, and water, and the pH of the composition is about 4.8 to about 5.4.

[0086] In another embodiment, about 20 mL of the pharmaceutical composition of the present disclosure comprises about 500 mg of retifanlimab, about 3.6 mg of glacial acetic acid, about 19 mg of sodium acetate trihydrate, about 1800 mg of sucrose, about 2 mg of PS80, and water, and the pH of the composition is about 5.1. In another embodiment, about 20 mL of the pharmaceutical composition of the present disclosure comprises about 500 mg of retifanlimab, about 3.6 mg of glacial acetic acid, about 19 mg of sodium acetate trihydrate, about 1800 mg of sucrose, about 2 mg of PS80, and water, and the pH of the composition is about 4.8 to about 5.4.

[0087] In one embodiment, the osmolality of the pharmaceutical composition of the present disclosure is about 200 to about 400 mOsm / kg·H2O. In another embodiment, the osmolality of the pharmaceutical composition of the present disclosure is about 225 to about 400 mOsm / kg·H2O. In another embodiment, the osmolality of the pharmaceutical composition of the present disclosure is about 250 to about 375 mOsm / kg·H2O. In another embodiment, the osmolality of the pharmaceutical composition of the present disclosure is about 250 to about 355 mOsm / kg·H2O. In another embodiment, the osmolality of the pharmaceutical composition of the present disclosure is about 260 to about 340 mOsm / kg·H2O.

[0088] In certain embodiments, the pharmaceutical composition of the present disclosure is sterile. In one embodiment, the pharmaceutical composition of the present disclosure is non-pyrogenic. The present disclosure further provides an embodiment of the pharmaceutical composition, sealed package, or kit, wherein the water is sterile, non-pyrogenic, distilled water. In another embodiment, the water in the sealed package, kit, or pharmaceutical composition of the present disclosure is Water for Injection, USP, or equivalent thereof.

[0089] In one embodiment, the pharmaceutical composition of the present disclosure is stable for at least about 3 months at about 25° C. In another embodiment, the pharmaceutical composition of the present disclosure maintains the monomeric purity of retifanlimab for at least about 3 months at about 25° C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 3 months at about 25° C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 3% or less at about 25° C. In another embodiment, the pharmaceutical composition of the present disclosure maintains the charge heterogeneity profile of retifanlimab for at least about 3 months at about 25° C. In another embodiment, the decrease of main charge peak (MCP) of retifanlimab in the pharmaceutical composition of the present disclosure is about 20% or less at about 3 months at about 25° C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 20% or less at about 25° C. in about 3 months.

[0090] In one embodiment, the pharmaceutical composition of the present disclosure is stable for at least about 6 months at about 25° C. In another embodiment, the pharmaceutical composition of the present disclosure maintains the monomeric purity of retifanlimab for at least about 6 months at about 25° C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 6 months at about 25° C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 3% or less at about 6 months at about 25° C. In another embodiment, the pharmaceutical composition of the present disclosure maintains the charge heterogeneity profile of retifanlimab for at least about 6 months at about 25° C. In another embodiment, the reduction of MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 20% or less at about 6 months at about 25° C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 20% or less at about 25° C. in about 6 months.

[0091] In one embodiment, the pharmaceutical composition of the present disclosure is stable at about 2°C to about 8°C for at least about 18 months. In another embodiment, the pharmaceutical composition of the present disclosure maintains the monomeric purity of retifanlimab at about 2°C to about 8°C for at least about 18 months. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 18 months at about 2°C to about 8°C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 4% or less at about 18 months at about 2°C to about 8°C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 3% or less at about 18 months at about 2°C to about 8°C. In another embodiment, the pharmaceutical composition of the present disclosure maintains the charge heterogeneity profile of retifanlimab at about 2°C to about 8°C for at least about 18 months. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less in about 18 months at about 2°C to about 8°C. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is about 6% or less in about 18 months at about 2°C to about 8°C. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure or in the dosing solution of the present disclosure is about 5% or less in about 18 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less in about 18 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 6% or less in about 18 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less over about 18 months at about 2°C to about 8°C.

[0092] In one embodiment, the pharmaceutical composition of the present disclosure is stable at about 2°C to about 8°C for about 24 months. In another embodiment, the pharmaceutical composition of the present disclosure maintains the monomeric purity of retifanlimab at about 2°C to about 8°C for about 24 months. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 24 months at about 2°C to about 8°C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 4% or less at about 24 months at about 2°C to about 8°C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 3% or less at about 24 months at about 2°C to about 8°C. In another embodiment, the pharmaceutical composition of the present disclosure maintains the charge heterogeneity profile of retifanlimab at about 2°C to about 8°C for at least about 24 months. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less in about 24 months at about 2°C to about 8°C. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 6% or less in about 24 months at about 2°C to about 8°C. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less in about 24 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less in about 24 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 6% or less in about 24 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less in about 24 months at about 2°C to about 8°C.

[0093] In one embodiment, the pharmaceutical composition of the present disclosure is stable at about 2°C to about 8°C for about 36 months. In another embodiment, the pharmaceutical composition of the present disclosure maintains the monomeric purity of retifanlimab at about 2°C to about 8°C for about 36 months. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 36 months at about 2°C to about 8°C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 4% or less at about 36 months at about 2°C to about 8°C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 3% or less at about 36 months at about 2°C to about 8°C. In another embodiment, the pharmaceutical composition of the present disclosure maintains the charge heterogeneity profile of retifanlimab at about 2°C to about 8°C for at least about 36 months. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less at about 36 months at about 2°C to about 8°C. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 6% or less at about 36 months at about 2°C to about 8°C. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 36 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less at about 36 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 6% or less at about 36 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 36 months at about 2°C to about 8°C.

[0094] In one embodiment, the pharmaceutical composition of the present disclosure is stable at about 2°C to about 8°C for about 48 months. In another embodiment, the pharmaceutical composition of the present disclosure maintains the monomeric purity of retifanlimab at about 2°C to about 8°C for about 48 months. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 48 months at about 2°C to about 8°C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 4% or less at about 2°C to about 8°C for about 48 months. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 3% or less at about 2°C to about 8°C for about 48 months. In another embodiment, the decrease of MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less at about 48 months at about 2°C to about 8°C. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 6% or less at about 48 months at about 2°C to about 8°C. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 48 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less at about 48 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 6% or less at about 48 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 48 months at about 2°C to about 8°C.

[0095] In one embodiment, the pharmaceutical composition of the present disclosure is stable at about 2°C to about 8°C for about 60 months. In another embodiment, the pharmaceutical composition of the present disclosure maintains the monomeric purity of retifanlimab at about 2°C to about 8°C for about 60 months. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less in about 60 months at about 2°C to about 8°C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 4% or less in about 60 months at about 2°C to about 8°C. In another embodiment, the loss of monomeric purity of retifanlimab in the pharmaceutical composition of the present disclosure is about 3% or less in about 60 months at about 2°C to about 8°C. In another embodiment, the decrease of MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less in about 60 months at about 2°C to about 8°C. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 6% or less at about 2°C to about 8°C in about 60 months. In another embodiment, the decrease in MCP of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 2°C to about 8°C in about 60 months. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 7% or less at about 60 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 6% or less at about 60 months at about 2°C to about 8°C. In another embodiment, the increase in AV of retifanlimab in the pharmaceutical composition of the present disclosure is about 5% or less at about 60 months at about 2°C to about 8°C.

[0096] The present disclosure also provides a container containing the pharmaceutical composition of the present disclosure. The present disclosure further provides a pharmaceutical pack or kit comprising one or more containers containing the pharmaceutical composition of the present disclosure. In one embodiment, the container is a vial (e.g., a single-dose vial). In one embodiment, the pharmaceutical pack or kit of the present disclosure contains a vial (e.g., a single-dose vial). In another embodiment, the pharmaceutical pack or kit of the present disclosure contains two or more vials. In another embodiment, the vial contains about 10 mL of the pharmaceutical composition of the present disclosure containing about 250 mg of retifanlimab, such that the concentration of retifanlimab is about 25 mg / mL per vial. In another embodiment, the vial contains about 15 mL of the pharmaceutical composition of the present disclosure containing about 375 mg of retifanlimab, such that the concentration of retifanlimab is about 25 mg / mL per vial. In another embodiment, the vial contains about 20 mL of the pharmaceutical composition of the present disclosure, including about 500 mg of retifanlimab, such that the concentration of retifanlimab is about 25 mg / mL per vial. It will be understood that the vial may contain an excess volume of the pharmaceutical composition of the present disclosure to ensure sufficient volume to withdraw 10 mL (250 mg), 15 mL (375 mg), and 20 mL (500 mg) of retifanlimab for dose delivery.

[0097] In addition, one or more other prophylactic or therapeutic agents useful for treating a disease can also be included in the pharmaceutical pack or kit of the present disclosure. Optionally, such one or more containers can be associated with a notice in a format prescribed by a government agency regulating the manufacture, use, or sale of pharmaceutical or biological products, the notice reflecting approval by the agency for manufacture, use, or sale for administration to humans. Optionally, a product label is associated with one or more of the containers, the product label including one or more instructions and / or instructions for preparing and administering a dosage solution containing the retifanlimab composition.

[0098] The present disclosure provides a kit comprising a pharmaceutical composition of the present disclosure that can be used in the method of the present disclosure. In the kit, the pharmaceutical composition of the present disclosure is generally packaged in an airtight container, such as an ampoule, a vial, a sachet, or other suitable container, and the container can indicate the amount of one or more ingredients contained therein. The container can be made of any pharma- ceutically acceptable material, such as glass, resin, plastic, or other suitable material. In one embodiment, the container is a borosilicate glass vial. In another embodiment, the container is a single-dose 10 mL USP Type I borosilicate glass vial. In another embodiment, the 10 mL container contains about 250 mg of retifanlimab in a volume of 10 mL. In another embodiment, the container is a single-dose 20 mL USP Type I borosilicate glass vial. In another embodiment, the 20 mL container contains about 375 mg of retifanlimab in a volume of 15 mL. In another embodiment, the 20 mL container contains about 500 mg of retifanlimab in a volume of 20 mL. In one embodiment, the container is aseptically filled. In one embodiment, the pharmaceutical composition of the present disclosure constituting the kit is supplied as a liquid solution. Such liquid solutions can be stored in the original container at about 2°C to about 8°C until ready for administration. However, such solutions can also be stored at room temperature (about 25°C) for short periods of time. In one embodiment, the pharmaceutical composition has a shelf life of at least about 18 months at about 2°C to about 8°C. In one embodiment, the pharmaceutical composition of the present invention has a shelf life of at least about 24 months at about 2°C to about 8°C. In one embodiment, the pharmaceutical composition has a shelf life of at least about 36 months at about 2°C to about 8°C. In one embodiment, the pharmaceutical composition of the present disclosure has a shelf life of at least about 48 months at about 2°C to about 8°C. In one embodiment, the pharmaceutical composition of the present disclosure has a shelf life of at least about 60 months at about 2°C to about 8°C. In other embodiments, the pharmaceutical compositions of the present disclosure have a shelf life of at least about 3 months at about 25° C. In other embodiments, the pharmaceutical compositions of the present disclosure have a shelf life of at least about 6 months at about 25° C.The kit may further include, in one or more containers, one or more other prophylactic and / or therapeutic agents that may be used in the treatment of cancer; and / or the kit may further include one or more antibodies, e.g., cytotoxic antibodies, that bind to one or more cancer antigens associated with cancer. In certain embodiments, the other prophylactic or therapeutic agent is a chemotherapeutic agent. In other embodiments, the prophylactic or therapeutic agent is a biological or hormonal therapeutic agent.

[0099] In one embodiment, the kit of the present disclosure comprises: a) a container containing a pharmaceutical composition, the composition comprising about 10 mg / mL to about 100 mg / mL of retifanlimab, about 5 mM to about 30 mM of acetate, about 50 mg / mL to about 130 mg / mL of sucrose, about 0.02 mg / mL to about 0.6 mg / mL of PS80, and water, wherein the pH of the composition is about 4.0 to about 6.5; and optionally b) instructions for administering said pharmaceutical composition to a subject in need thereof; Includes.

[0100] In one embodiment, the kit of the present disclosure comprises: a) a container containing a pharmaceutical composition, the composition comprising about 10 mg / mL to about 100 mg / mL of retifanlimab, about 7.5 mM to about 20 mM of acetate, about 50 mg / mL to about 130 mg / mL of sucrose, about 0.05 mg / mL to about 0.6 mg / mL of PS80, and water, wherein the pH of the composition is about 4.0 to about 6.5; and optionally b) instructions for administering said pharmaceutical composition to a subject in need thereof; Includes.

[0101] In one embodiment, the kit of the present disclosure comprises: a) a container containing a pharmaceutical composition, the composition comprising about 20 mg / mL to about 30 mg / mL of retifanlimab, about 9 mM to about 11 mM of acetate, 76 mg / mL to about 104 mg / mL of sucrose, about 0.08 mg / mL to about 0.53 mg / mL of PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7; and optionally b) instructions for administering said pharmaceutical composition to a subject in need thereof; Includes.

[0102] In one embodiment, the container can contain about 25 mg / mL retifanlimab, about 10 mM acetate, 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is about 5.1. In another embodiment, the container can contain about 25 mg / mL retifanlimab, about 10 mM acetate, 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is 4.8 to 5.4.

[0103] In one embodiment, the kit of the present disclosure comprises: a) a container containing a pharmaceutical composition, the composition comprising about 10 mg / mL to about 100 mg / mL of retifanlimab, about 0.05 mg / mL to about 0.35 mg / mL of glacial acetic acid, about 0.80 mg / mL to about 2.0 mg / mL of sodium acetate trihydrate, about 50 mg / mL to about 130 mg / mL of sucrose, about 0.02 mg / mL to about 0.6 mg / mL of PS80, and water, wherein the pH of the composition is about 4.0 to about 6.5; and optionally b) instructions for administering said pharmaceutical composition to a subject in need thereof; Includes.

[0104] In one embodiment, the kit of the present disclosure comprises: a) a container containing a pharmaceutical composition, the composition comprising about 10 mg / mL to about 100 mg / mL of retifanlimab, about 0.1 mg / mL to about 0.3 mg / mL of glacial acetic acid, about 0.80 mg / mL to about 2.0 mg / mL of sodium acetate trihydrate, about 50 mg / mL to about 130 mg / mL of sucrose, about 0.05 mg / mL to about 0.6 mg / mL of PS80, and water, wherein the pH of the composition is about 4.0 to about 6.5; and optionally b) instructions for administering said pharmaceutical composition to a subject in need thereof; Includes.

[0105] In one embodiment, the kit of the present disclosure comprises: a) a container containing a pharmaceutical composition, the composition comprising about 20 mg / mL to about 30 mg / mL of retifanlimab, about 0.16 mg / mL to about 0.20 mg / mL of glacial acetic acid, about 0.86 mg / mL to about 1.1 mg / mL of sodium acetate trihydrate, about 76 mg / mL to about 104 mg / mL of sucrose, about 0.08 mg / mL to about 0.53 mg / mL of PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7; and optionally b) instructions for administering said pharmaceutical composition to a subject in need thereof; Includes.

[0106] In one embodiment, the kit of the present disclosure comprises: a) a container containing a pharmaceutical composition, the composition comprising about 22.5 mg / mL to about 27.5 mg / mL of retifanlimab, about 0.16 mg / mL to about 0.20 mg / mL of glacial acetic acid, about 0.86 mg / mL to about 1.1 mg / mL of sodium acetate trihydrate, 76 mg / mL to about 104 mg / mL of sucrose, about 0.08 mg / mL to about 0.53 mg / mL of PS80, and water, wherein the pH of the composition is about 4.5 to about 5.7; and optionally b) instructions for administering said pharmaceutical composition to a subject in need thereof; Includes.

[0107] In one embodiment, the container can contain about 25 mg / mL retifanlimab, about 0.18 mg / mL glacial acetic acid, about 0.95 mg / mL sodium acetate trihydrate, about 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is about 5.1. In another embodiment, the container can contain about 25 mg / mL retifanlimab, about 0.18 mg / mL glacial acetic acid, about 0.95 mg / mL sodium acetate trihydrate, about 90 mg / mL sucrose, about 0.1 mg / mL PS80, and water, and the pH of the composition is 4.8 to 5.4.

[0108] The water in the compositions, containers, and kits of this disclosure can be sterile, non-pyrogenic, distilled water and can be water for injection, USP, or equivalent.

[0109] In one embodiment, the pharmaceutical kit of the present disclosure can include instructional materials. The instructional materials included in the pharmaceutical kit of the present disclosure can instruct to administer the provided pharmaceutical composition in combination with additional agents that can be provided in the same pharmaceutical kit or in a separate pharmaceutical kit. The instructional materials can instruct to administer the provided pharmaceutical composition at regular or irregular intervals, such as about once every two weeks, about once every three weeks, about once every four weeks, or more or less frequently. The instructional materials can instruct that one container of the provided pharmaceutical composition contains about 25 mg / mL (e.g., 250 mg / 10 mL; 375 mg / 15 mL; or 500 mg / 20 mL) of retifanlimab. The instructional materials can instruct to administer the provided pharmaceutical composition at a weight-based therapeutic dose of about 3 mg / kg to about 10 mg / kg, about 3 mg / kg, or about 10 mg / kg, or at a flat dose of about 375 mg, about 500 mg, or about 750 mg. The instructional material may instruct to dilute the provided pharmaceutical composition (e.g., in 0.9% sodium chloride or D5W) prior to administration. The instructional material included in the pharmaceutical kit of the present disclosure may combine any set of such information (e.g., the instructional material may instruct to dilute the retifanlimab pharmaceutical composition in 0.9% sodium chloride or D5W and administer it at a weight-based therapeutic dose of about 3 mg / kg or about 10 mg / kg, or at a flat dose of about 375 mg, about 500 mg, or about 750 mg, and to administer the dose at regular or irregular intervals, such as about once every 2 weeks, about once every 3 weeks, about once every 4 weeks, or more or less frequently). The instructional material may instruct regarding the mode of administration of the provided pharmaceutical composition, for example, to administer the pharmaceutical composition by intravenous (IV) infusion. The instructional material included in the pharmaceutical kits of the present disclosure may instruct regarding the duration or timing of said administration, for example, to administer a provided pharmaceutical composition by intravenous (IV) infusion over about 30 minutes, or over about 60 minutes, or over a longer or shorter duration.

[0110] In one embodiment, the instructional material of the pharmaceutical kit of the present disclosure instructs diluting the provided pharmaceutical composition in 0.9% sodium chloride to obtain a dosing solution, hi another embodiment, the instructional material of the pharmaceutical kit of the present disclosure instructs diluting the provided pharmaceutical composition in D5W to obtain a dosing solution.

[0111] In one embodiment, the instructional material of the pharmaceutical kit of the present disclosure provides a method of administering a pharmaceutical composition of the present disclosure to a subject in need thereof, the method comprising: a) diluting the pharmaceutical composition in a container in 0.9% sodium chloride to obtain a dosing solution; b) inverting the container to mix the diluted solution; and c) attaching the container containing the dosing solution to a device for administration to the subject. Includes.

[0112] In one embodiment, the instructional material of the sealed package of the present disclosure provides a method of administering a pharmaceutical composition of the present disclosure to a subject in need thereof, the method comprising: a) diluting the pharmaceutical composition in D5W in a container to obtain a dosing solution; b) inverting the container to mix the diluted solution; and c) attaching the container containing the dosing solution to a device for administration to the subject. Includes.

[0113] In one embodiment, the container is an IV bag containing 0.9% sodium chloride, hi another embodiment, the container is an IV bag containing D5W.

[0114] In one embodiment, administration of the dosing solution is by intravenous (IV) infusion over a period of about 30 minutes to about 120 minutes, about 30 minutes, or about 60 minutes.

[0115] In one embodiment, the pharmaceutical composition of the present disclosure is diluted to obtain a therapeutic dose of about 3 mg / kg of body weight of retifanlimab in the dosing solution. In another embodiment, the pharmaceutical composition of the present disclosure is diluted to obtain a therapeutic dose of about 10 mg / kg of body weight of retifanlimab in the dosing solution.

[0116] In one embodiment, the pharmaceutical composition of the present disclosure is diluted to obtain a uniform dose of about 375 mg of retifanlimab in the dosing solution. In another embodiment, the pharmaceutical composition of the present disclosure is diluted to obtain a uniform dose of about 500 mg of retifanlimab in the dosing solution. In another embodiment, the pharmaceutical composition of the present disclosure is diluted to obtain a uniform dose of about 750 mg of retifanlimab in the dosing solution.

[0117] The instructional material included in the pharmaceutical kits of the present disclosure can instruct on the appropriate or desired use of the included pharmaceutical compositions, e.g., to administer a provided pharmaceutical composition in a prophylactically or therapeutically effective amount for the treatment of cancer, such as: adrenal gland cancer, AIDS-related cancer, alveolar soft part sarcoma, anal cancer (including squamous cell carcinoma of the anal canal (SCAC)), bladder cancer, bone cancer, brain and spinal cord cancer, breast cancer (HER2 +breast cancer or triple-negative breast cancer (TNBC), carotid body tumor, cervical cancer, HPV-associated cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, desmoplastic small round cell tumor, ependymoma, endometrial cancer (including unselected endometrial cancer, MSI-high endometrial cancer, dMMR endometrial cancer, and / or DNA polymerase epsilon (POLE) exonuclease domain mutation-positive endometrial cancer), Ewing's sarcoma, extraskeletal myxoid chondrosarcoma, gallbladder or bile duct cancer (including cholangiocarcinoma), gastric cancer cancer), esophagogastric junction (GEJ) cancer, gestational trophoblastic disease, germ cell tumors, gliomas, glioblastomas, head and neck cancer (including squamous cell carcinoma of the head and neck (SCCHN)), hematologic malignancies, hepatocellular carcinoma, pancreatic islet cell tumors, Kaposi's sarcoma, kidney cancer (including renal cell carcinoma (RCC), clear cell RRC, papillary RCC, and chromophobe RCC), leukemia (including acute myeloid leukemia), liposarcoma / malignant lipomatous tumors, liver cancer (including hepatocellular carcinoma (HCC)), lymphoma (including diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL)), lung cancer (small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) ), medulloblastoma, melanoma (including uveal melanoma), meningioma, mesothelioma (including mesothelial pharyngeal carcinoma), multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumor, ovarian cancer, pancreatic cancer, papillary thyroid cancer, parathyroid tumor, childhood cancer, peripheral nerve sheath tumor, pharyngeal cancer, pheochromocytoma, pituitary tumor, prostate cancer (including metastatic castration-resistant prostate cancer (mCRPC)), posterior uveal melanoma, renal metastatic carcinoma, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin cancer (including Merkel cell carcinoma), small round blue cell tumor of childhood (including neuroblastoma and rhabdomyosarcoma), soft tissue sarcoma, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid cancer, urothelial carcinoma, and uterine cancer.

[0118] The instruction material included in the pharmaceutical kit of the present disclosure can instruct the administration of the pharmaceutical composition to a cancer selected from the group consisting of: anal cancer, breast cancer, colorectal cancer, endometrial cancer, gastric cancer, GEJ cancer, glioma, head and neck cancer, renal cancer, liver cancer, lung cancer, lymphoma, melanoma, multiple myeloma, metastatic renal cancer, ovarian cancer, pancreatic cancer, ovarian cancer, prostate cancer, skin cancer, urothelial cancer, and uterine cancer.

[0119] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure instructs administering the pharmaceutical composition for the treatment of anal cancer, hi another embodiment, the anal cancer is SCAC.

[0120] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure instructs administering the pharmaceutical composition for the treatment of lung cancer, hi another embodiment, the lung cancer is NSCLC.

[0121] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure instructs administering the pharmaceutical composition for the treatment of endometrial cancer, hi another embodiment, the endometrial cancer is MSI-high endometrial cancer, dMMR endometrial cancer, and / or POLE exonuclease domain mutation positive endometrial cancer.

[0122] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure instructs administering the pharmaceutical composition for the treatment of skin cancer, hi another embodiment, the skin cancer is Merkel cell carcinoma.

[0123] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure instructs administering the pharmaceutical composition for the treatment of head and neck cancer, hi another embodiment, the head and neck cancer is SCCHN.

[0124] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure instructs administering the pharmaceutical composition for the treatment of prostate cancer, hi another embodiment, the prostate cancer is mCRPC.

[0125] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure instructs administering the pharmaceutical composition for the treatment of renal cancer. In another embodiment, the renal cancer is RCC. In another embodiment, the renal cancer is clear cell RCC.

[0126] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure provides instructions for administering the pharmaceutical composition for the treatment of melanoma.

[0127] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure provides instructions for administering the pharmaceutical composition for the treatment of urothelial carcinoma.

[0128] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure provides instructions for administering the pharmaceutical composition for the treatment of squamous cell carcinoma.

[0129] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure provides instructions for administering the pharmaceutical composition for the treatment of glioma.

[0130] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure provides instructions for administering the pharmaceutical composition for the treatment of cervical cancer.

[0131] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure provides instructions for administering the pharmaceutical composition for the treatment of kidney cancer.

[0132] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure provides instructions for administering the pharmaceutical composition for the treatment of chromophobe renal cell carcinoma.

[0133] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure provides instructions for administering the pharmaceutical composition for the treatment of metastatic kidney cancer.

[0134] In one embodiment, the instructional material included in the pharmaceutical kit of the present disclosure provides instructions for administering the pharmaceutical composition for the treatment of uterine cancer.

[0135] In any of the above embodiments, the instructional material included in the pharmaceutical kit of the present disclosure can instruct the pharmaceutical composition to be administered for the treatment of a cancer as described above, wherein the cancer is a metastatic cancer. In some embodiments, the instructional material included in the pharmaceutical kit of the present disclosure can instruct the pharmaceutical composition to be administered for the treatment of a cancer as described above, wherein the cancer is a primary cancer.

[0136] In some embodiments, the instructional material included in the pharmaceutical kit of the present disclosure can instruct the pharmaceutical composition to be administered for the treatment of a cancer as described above before, during, or after another treatment for the cancer. In certain such embodiments, the instructional material can instruct the pharmaceutical composition to be administered as a neoadjuvant therapy for the treatment of a cancer as described above. In other such embodiments, the instructional material can instruct the pharmaceutical composition to be administered as an adjuvant therapy for the treatment of a cancer as described above. In other such embodiments, the instructional material can instruct the pharmaceutical composition to be administered as a component of a combination therapy for the treatment of a cancer as described above.

[0137] In some embodiments, the instructional material included in the pharmaceutical kit of the present disclosure can instruct the pharmaceutical composition to be administered for the treatment of a cancer expressing PD-L1, as described above. The instructional material can further specify a particular PD-L1 expression measurement and score, such as a Tumor Proportion Score (TPS) of 1% or greater, or a Combined Positive Score (CPS) of 1 or greater. The instructional material can further specify that such PD-L1 expression score is determined by a test approved for use by a regulatory agency (e.g., approved by the FDA). Such tests have already been documented; for example, FDA approved tests are listed on the FDA website: fda.gov / CompanionDiagnostics, including, for example, PD-L1 IHC 22C3 pharmDx, and further tests are described in Cheung et al., (2019), “Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).” Appl Immunohistochem Mol Morphol 27 (10):699-714.

[0138] The pharmaceutical compositions of the present disclosure can be provided for the treatment, prevention, and amelioration of one or more symptoms associated with a disease, disorder, or infection by administering a therapeutically or prophylactically effective amount of retifanlimab to a subject. In one embodiment, the pharmaceutical composition is substantially purified (i.e., substantially free of substances that limit the effectiveness of the composition or produce undesirable side effects) as determined by any suitable method. In another embodiment, the subject is an animal, including a mammal, such as a non-primate (e.g., bovine, equine, feline, canine, rodent, etc.) or a primate (e.g., monkey, such as cynomolgus monkey, human, etc.). In one embodiment, the subject is a human. The terms "subject" and "patient" are used interchangeably herein.

[0139] Methods of administering the pharmaceutical compositions (i.e., retifanlimab compositions) of the present disclosure include, but are not limited to, parenteral administration (e.g., intravenously). In one embodiment, the pharmaceutical compositions (i.e., retifanlimab compositions) of the present disclosure are administered intravenously. The pharmaceutical compositions of the present disclosure may be administered with other pharmacologic active agents, such as: chemotherapeutic agents, including but not limited to, antimetabolite chemotherapeutic agents (including pemetrexed), platinum-based chemotherapeutic agents (including, for example, cisplatin and carboplatin), and taxane-based chemotherapeutic agents (including, for example, paclitaxel and nab-paclitaxel); biologics, including but not limited to, antibodies and antibody-like molecules, including those that bind to cancer antigens. Such cancer antigens include, but are not limited to, 5T4, B7-H3, CD19, CD20, CD51, CD123, DR5, EGFR, EpCam, GD2, gpA33, HER2, ROR-1, TAG-72, and / or VEGFR2. A number of antibodies and antibody-like molecules that bind to cancer antigens such as those mentioned above have been described, including, but not limited to, bevacizumab, cetuximab, enoblituzumab, flotetuzumab, margetuximab, ofatumumab, panitumumab, rituximab, trastuzumab, etc.

[0140] In one embodiment, the amount of the pharmaceutical composition (i.e., retifanlimab composition) of the present disclosure is determined using a weight-based dose of retifanlimab. The term "weight-based dose" as used herein refers to the individual amount of retifanlimab administered per unit body weight of the patient, e.g., milligrams of retifanlimab per kilogram of subject body weight (mg / kg body weight; abbreviated herein as "mg / kg"). The calculated dose is administered based on the subject's body weight at baseline. Typically, a significant change in body weight (e.g., at least plus or minus about 10% or more) from the baseline or established plateau body weight will prompt a recalculation of the dose. Single or multiple doses may be administered.

[0141] In certain embodiments, retifanlimab is administered to a subject in need thereof at a weight-based dose of about 3 mg / kg to about 10 mg / kg. In certain embodiments, retifanlimab is administered to a subject in need thereof at a dose of about 3 mg / kg or about 10 mg / kg. With respect to weight-based doses, the term "about" is intended to refer to a range of ±10% of the stated dose, so that, for example, a dose of about 10 mg / kg would be 9 mg / kg to 11 mg / kg.

[0142] In one embodiment, the amount of the pharmaceutical composition (i.e., retifanlimab composition) of the present disclosure is determined using a flat dose of retifanlimab. As used herein, the term "flat dose" refers to a dose that is not dependent on the patient's body weight and includes a physically discrete unit of retifanlimab suitable as a single dose for a subject to be treated, e.g., each unit contains a predetermined amount of retifanlimab (e.g., calculated to produce a desired therapeutic effect) associated with a pharmaceutical carrier and optionally associated with additional agents. Single or multiple flat doses may be administered.

[0143] Retifanlimab can be administered as a weight-based dose (e.g., a dose in mg / kg of patient's body weight) or as a flat dose (e.g., a dose of 375 mg). In general, multiple doses of retifanlimab (and optionally additional pharmaceutical agents) can be used to provide a subject with a therapeutically or prophylactically effective amount of retifanlimab. As used herein, the term "dose" refers to a specified amount of drug administered at one time. The term "dosage" refers to the administration of multiple doses at a specific amount and frequency over a specified period of time, and thus the term "dosage" includes chronological characteristics such as periodicity.

[0144] As used herein, a "therapeutically effective amount" of retifanlimab of the pharmaceutical composition of the present disclosure when used to treat cancer is an amount that can slow the progression of cancer; reduce the number of cancer cells in a body fluid (e.g., blood, peripheral cells, or lymph), tissue, or organ (cytotoxic); maintain the number of cancer cells relatively constant (cytostatic); reduce tumor size, inhibit metastasis, inhibit tumor growth, and / or alleviate one or more symptoms of cancer. The therapeutically effective amount of retifanlimab for use in formulating the pharmaceutical composition of the present disclosure is provided herein and / or can be determined, for example, by a medical professional, taking into account the type of cancer to be treated, the route of delivery, age, weight, the severity of the subject's symptoms, and the subject's response pattern. As used herein, a "prophylactically effective amount" of retifanlimab of the pharmaceutical composition of the present disclosure when used to prevent cancer is an amount that can prevent the occurrence or recurrence of cancer, or reduce the risk of the occurrence or recurrence of cancer. As used herein, treating cancer with the pharmaceutical composition, container, kit, or method of the present disclosure can include, for example, administering a therapeutically or prophylactically effective amount of retifanlimab to a subject in need thereof.

[0145] In certain embodiments, retifanlimab is administered to a subject in need thereof at a flat dose of about 375 mg. In certain embodiments, retifanlimab is administered to a subject in need thereof at a flat dose of about 500 mg. In certain embodiments, retifanlimab is administered to a subject in need thereof at a flat dose of about 750 mg. With respect to flat doses, the term "about" is intended to refer to a range of ±10% of the stated dose, and thus a dose of about 500 mg / kg would be 450 mg to 550 mg.

[0146] A dose of the pharmaceutical composition of the present disclosure (i.e., a dose of the retifanlimab composition) can be administered at periodic intervals over a period of time (a course of treatment) sufficient to encompass at least 2 doses, at least 4 doses, at least 6 doses, at least 12 doses, or at least 24 doses, or more than 24 doses. Such administration of the pharmaceutical composition of the present disclosure at periodic intervals over a period of time can be considered a "course of treatment." For example, a dosage can be administered once every 2 weeks ("Q2W"), once every 3 weeks ("Q3W"), once every 4 weeks ("Q4W"), or for a shorter or longer period of time. Such periodic administration can continue over a period of time, for example, from about 1 to 52 weeks, or for more than about 52 weeks. Such a course of treatment can be divided into multiple increments of shorter intervals, for example, from 2 to 8 weeks, during which a set number of doses are administered. The dosage and / or frequency of administration may be the same or different during each cycle.Factors that may affect the dosing and timing required to effectively treat a subject include, for example, the severity of the subject's disease or disorder, the formulation, route of delivery, previous treatments, overall health, and / or age, and the presence of other diseases in the subject's body.Furthermore, treatment of a subject with a therapeutically effective amount of a compound may include a single treatment or a series of multiple treatments.

[0147] A "dosing regimen" is the administration of a dosage in which a patient is administered a predetermined dose (or a set of a plurality of such doses) at a predetermined frequency (or a set of a plurality of such frequencies) at one or more predetermined periodicities. One dosing regimen of the present disclosure comprises administration of the retifanlimab composition of the present disclosure Q2W at a dose of about 1 mg / kg. Another dosing regimen of the present disclosure comprises administration of the retifanlimab composition of the present disclosure Q2W or Q4W at a dose of about 3 mg / kg. Another dosing regimen of the present disclosure comprises administration of the retifanlimab composition of the present disclosure Q2W or Q4W at a dose of about 10 mg / kg. Another dosing regimen of the present disclosure comprises administration of the retifanlimab composition of the present disclosure Q3W at a flat dose of about 375 mg. Another dosing regimen of the present disclosure comprises administration of the retifanlimab composition of the present disclosure Q4W at a flat dose of about 500 mg. Another dosing regimen of the present disclosure comprises administration of the retifanlimab composition of the present disclosure Q4W at a flat dose of about 750 mg.

[0148] In certain embodiments of the present disclosure, it is specifically contemplated that the administration of the pharmaceutical composition is performed at a predetermined frequency or periodicity or within about 1-3 days of such scheduled intervals, such that administration is performed 1-3 days before, 1-3 days after, or on the scheduled dosing date, for example, once every 3 weeks (± 3 days). In such embodiments, the retifanlimab composition of the present disclosure can be administered by IV infusion. In certain embodiments, the pharmaceutical composition of the present disclosure is administered by IV infusion, which may be continuous or discontinuous intravenous infusion. In certain embodiments, the retifanlimab composition is administered by IV infusion according to any of the dosing regimens of the present disclosure for a duration of at least about 1 month or more, at least about 3 months or more, at least about 4 months, at least about 6 months or more, or at least about 12 months, or more than about 12 months. A treatment period of at least about 6 months or more, or at least about 12 months or more than about 12 months, or until reduction or remission of disease, stable disease, or unmanageable toxicity is observed. In certain embodiments, treatment is continued for a period of time after reduction or remission of disease or stable disease is observed, hi certain embodiments, treatment may be interrupted due to illness, adverse events, etc., and resumed upon resolution, reduction, or improvement of such illness, adverse events, etc.

[0149] In certain embodiments of the disclosed methods, the pharmaceutical composition (i.e., retifanlimab composition) is diluted in an infusion bag with a suitable diluent, e.g., 0.9% sodium chloride or D5W, for administration by IV infusion. Since infusion or allergic reactions may occur, premedication for prevention of such infusion reactions may be utilized, and precautions against anaphylaxis may be taken during administration of the antibody. In one embodiment, the IV infusion is administered to the subject over about 30 minutes to about 120 minutes, about 30 minutes to about 90 minutes, about 30 minutes to about 60 minutes, about 30 minutes, about 60 minutes, or about 120 minutes. In certain embodiments, the IV infusion is administered to the subject over about 30 minutes or about 60 minutes. In other embodiments, the IV infusion is administered to the subject over about 30 minutes.

[0150] The dosing solution containing the pharmaceutical composition (such as the retifanlimab composition of the present disclosure) is suitable for intravenous administration, for example, by gravity or using a static infusion pump. The retifanlimab dosing solution can be obtained by combining the retifanlimab composition of the present disclosure with 0.9% sodium chloride or D5W. In certain embodiments, the administration of the therapeutic dosage is over a period of at least 30 minutes or at least 60 minutes.

[0151] In some embodiments, a weight-based dose of about 3 mg / kg to about 10 mg / kg is administered to the patient or subject. In one embodiment, a weight-based dose of about 3 mg / kg is administered to the patient or subject. In another embodiment, a weight-based dose of about 10 mg / kg is administered to the patient or subject. In another particular embodiment, a weight-based dose of about 3 mg / kg to about 10 mg / kg is administered to the patient or subject Q2W. In another embodiment, a weight-based dose of about 3 mg / kg is administered Q2W. In another embodiment, a weight-based dose of about 10 mg / kg is administered Q2W. In another embodiment, a weight-based dose of about 3 mg / kg to about 10 mg / kg is administered Q3W. In another embodiment, a weight-based dose of about 3 mg / kg to about 10 mg / kg is administered Q3W. In another embodiment, a weight-based dose of about 10 mg / kg is administered Q3W. In another embodiment, a weight-based dose of about 3 mg / kg to about 10 mg / kg is administered Q4W. In another embodiment, a body weight based dose of about 10 mg / kg is administered Q4W.

[0152] In one embodiment, a flat dose of about 375 mg is administered to the patient or subject. In one embodiment, a flat dose of about 500 mg is administered to the patient or subject. In one embodiment, a flat dose of about 750 mg is administered to the patient or subject. In another embodiment, a flat dose of about 375 mg is administered Q2W. In another embodiment, a flat dose of about 500 mg is administered Q2W. In another embodiment, a flat dose of about 750 mg is administered Q2W. In another embodiment, a flat dose of about 375 mg is administered Q3W. In another embodiment, a flat dose of about 500 mg is administered Q3W. In another embodiment, a flat dose of about 750 mg is administered Q3W. In another embodiment, a flat dose of about 375 mg is administered Q4W. In another embodiment, a flat dose of about 500 mg is administered Q4W. In another embodiment, a flat dose of about 750 mg is administered Q4W.

[0153] In one embodiment, the administration of the dose as described above is over a period of at least about 30 minutes, or over a period of at least about 120 minutes. In another embodiment, the administration of the dose as described above is over a period of at least about 30 minutes, or over a period of at least about 90 minutes. In another embodiment, the administration of the dose as described above is over a period of at least about 30 minutes, or over a period of at least about 60 minutes. In another embodiment, the administration of the retifanlimab dosing solution is by continuous infusion over a period of at least about 30 minutes. In another embodiment, the administration of the retifanlimab dosing solution is by continuous infusion over a period of at least about 60 minutes.

[0154] To form a dosing solution, the pharmaceutical composition (i.e., the retifanlimab composition of the present disclosure) can be added to a container, such as an IV bag (nominal volume 100 mL or 250 mL) containing 0.9% sodium chloride or D5W. In one embodiment, the pharmaceutical composition of the present disclosure is gently mixed before being added to the container containing 0.9% sodium chloride or D5W. In one embodiment, the container is an IV bag. In one embodiment, the IV bag is a polyvinyl chloride (PVC) bag, a polyolefin copolymer (polypropylene and polyethylene) bag, a PVC bag containing di-2-ethylhexyl phthalate (DEHP), a polyamide-coated polyolefin bag, or an ethylene vinyl acetate (EVA) bag. In one embodiment, an in-line filter is used during administration. In one embodiment, the pore size of the filter is 0.2 μm, 5 μm, or 15 μm. In another embodiment, an in-line filter with a pore size of 0.2 μm is used. In another embodiment, the filter is a polyvinylidene fluoride or cellulose acetate filter. In another embodiment, the filter is a polyethersulfone (PES) filter. In some embodiments, a desired volume of a pharmaceutical composition of the present disclosure can be added to the IV bag and the dosing solution can be mixed, for example by gentle inversion.

[0155] In one embodiment, the prepared dosing solution is used immediately. In another embodiment, the prepared dosing solution is stored at about 25° C. for about 6 hours, or at about 2-8° C. for up to about 24 hours. In another embodiment, the prepared dosing solution stored at about 2-8° C. for up to about 24 hours is stored at room temperature for a 4 hour equilibration period prior to administration.

[0156] The pharmaceutical compositions, containers, and kits of the present disclosure can be used, e.g., in a therapeutically or prophylactically effective amount, in methods for the treatment of cancer, and in certain embodiments, for the treatment of cancers that express PD-L1. In some embodiments, the methods of the present disclosure comprise administering, e.g., in a therapeutically or prophylactically effective amount, a pharmaceutical composition of the present disclosure to a subject in need thereof for the treatment of cancer. In some embodiments, the cancers treated using the pharmaceutical compositions, containers, and kits of the present disclosure include: adrenal cancer, AIDS-related cancer, alveolar soft part sarcoma, anal cancer (including squamous cell carcinoma of the anal canal (SCAC)), bladder cancer, bone cancer, brain and spinal cord cancer, breast cancer (including HER2 +breast cancer or triple-negative breast cancer (TNBC), carotid body tumor, cervical cancer, HPV-associated cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, desmoplastic small round cell tumor, ependymoma, endometrial cancer (including unselected endometrial cancer, MSI-high endometrial cancer, dMMR endometrial cancer, and / or DNA polymerase epsilon (POLE) exonuclease domain mutation-positive endometrial cancer), Ewing's sarcoma, extraskeletal myxoid chondrosarcoma, gallbladder or bile duct cancer (including cholangiocarcinoma), gastric cancer cancer), esophagogastric junction (GEJ) cancer, gestational trophoblastic disease, germ cell tumors, gliomas, glioblastomas, head and neck cancer (including squamous cell carcinoma of the head and neck (SCCHN)), hematologic malignancies, hepatocellular carcinoma, pancreatic islet cell tumors, Kaposi's sarcoma, kidney cancer (including renal cell carcinoma (RCC), clear cell RRC, papillary RCC, and chromophobe RCC), leukemia (including acute myeloid leukemia), liposarcoma / malignant lipomatous tumors, liver cancer (including hepatocellular carcinoma (HCC)), lymphoma (including diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL)), lung cancer (small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) ), medulloblastoma, melanoma (including uveal melanoma), meningioma, mesothelioma (including mesothelial pharyngeal carcinoma), multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumor, ovarian cancer, pancreatic cancer, papillary thyroid cancer, parathyroid tumor, childhood cancer, peripheral nerve sheath tumor, pharyngeal cancer, pheochromocytoma, pituitary tumor, prostate cancer (including metastatic castration-resistant prostate cancer (mCRPC)), posterior uveal melanoma, renal metastatic carcinoma, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin cancer (including Merkel cell carcinoma), small round blue cell tumor of childhood (including neuroblastoma and rhabdomyosarcoma), soft tissue sarcoma, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid cancer, urothelial carcinoma, and uterine cancer.

[0157] In one embodiment, the pharmaceutical compositions of the present disclosure can be used for the treatment of a cancer selected from the group consisting of: anal cancer, breast cancer, colorectal cancer, endometrial cancer, gastric cancer, GEJ cancer, glioma, head and neck cancer, renal cancer, liver cancer, lung cancer, lymphoma, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, ovarian cancer, prostate cancer, metastatic renal cancer, skin cancer, urothelial cancer, and uterine cancer.

[0158] In one embodiment, the pharmaceutical compositions of the present disclosure are used to treat anal cancer, hi another embodiment, the anal cancer is SCAC.

[0159] In one embodiment, the pharmaceutical composition of the present disclosure is used for the treatment of lung cancer. In another embodiment, the lung cancer is NSCLC.

[0160] In one embodiment, the pharmaceutical composition of the present disclosure is used for the treatment of endometrial cancer, hi another embodiment, said endometrial cancer is MSI-high endometrial cancer, dMMR endometrial cancer, and / or POLE exonuclease domain mutation positive endometrial cancer.

[0161] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of skin cancer, hi another embodiment, the skin cancer is Merkel cell carcinoma.

[0162] In one embodiment, the pharmaceutical composition of the present disclosure is used for the treatment of head and neck cancer. In another embodiment, the head and neck cancer is SCCHN.

[0163] In one embodiment, the pharmaceutical composition of the present disclosure is used for the treatment of prostate cancer. In another embodiment, the prostate cancer is mCRPC.

[0164] In one embodiment, the pharmaceutical composition of the present disclosure is used for the treatment of renal cancer. In another embodiment, the renal cancer is RCC. In another embodiment, the renal cancer is clear cell RCC.

[0165] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of melanoma.

[0166] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of urothelial carcinoma.

[0167] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of squamous cell carcinoma.

[0168] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of glioma.

[0169] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of cervical cancer.

[0170] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of kidney cancer.

[0171] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of chromophobe renal cell carcinoma.

[0172] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of metastatic kidney cancer.

[0173] In one embodiment, the pharmaceutical compositions of the present disclosure are used for the treatment of uterine cancer.

[0174] In some embodiments, the pharmaceutical compositions of the present disclosure are used for the treatment of a cancer as described above, wherein the cancer is a metastatic cancer.In some embodiments, the pharmaceutical compositions of the present disclosure are used for the treatment of a cancer as described above, wherein the cancer is a metastatic cancer.

[0175] In certain of these embodiments, the pharmaceutical composition of the present disclosure is used as a neoadjuvant therapy for the treatment of such cancers. In certain of these embodiments, the pharmaceutical composition of the present disclosure is used as an adjuvant therapy for the treatment of such cancers. In other of these embodiments, the pharmaceutical composition of the present disclosure is used as a component of a combination therapy for the treatment of such cancers.

[0176] In certain embodiments, the pharmaceutical compositions of the present disclosure are used for the treatment of cancers as described above, wherein the cancer expresses PD-L1. Regulatory approved methods and tests for identifying cancers that express PD-L1 have been documented (see, e.g., the FDA website at fda.gov / CompanionDiagnostics), including, for example, PD-L1 IHC 22C3 pharmDx, and further tests are described in Cheung et al., (2019), "Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)." Appl Immunohistochem Mol Morphol 27 (10):699-714. EXAMPLES

[0177] Having now generally described the present disclosure, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended to limit the disclosure.

[0178] Example 1 Development of pharmaceutical compositions containing retifanlimab A stable antioxidant-free pharmaceutical composition comprising retifanlimab ("retifanlimab drug product (DP) composition") was prepared as a liquid composition in a vial. As disclosed herein, retifanlimab comprises a PD-1 binding domain comprising a heavy chain having the amino acid sequence of SEQ ID NO: 1 and a light chain having the amino acid sequence of SEQ ID NO: 2. The light chain comprises a variable domain (VL) comprising CDRL1, CDRL2, and CDRL3 of retifanlimab. PD-1), and the heavy chain comprises a variable domain (VH) comprising CDRH1, CDRH2, and CDRH3 of retifanlimab. PD-1 ).

[0179] 1.1. Target Product Profile of Exemplary Retifanlimab DP Compositions The target product profiles of exemplary retifanlimab DP compositions for 250 mg, 375 mg, and 500 mg vials are shown in Table 1 below.

[0180] [Table 1]

[0181] 1.2. Overview of Development of Exemplary Retifanlimab Formulation (DP) Compositions First, a protein concentration of 10 mg / mL was selected to determine the effects of pH, excipients, and surfactants. The stability of the retifanlimab product was evaluated at different storage temperatures, agitation stress at room temperature, and freeze-thaw conditions. After selecting the optimal formulation buffer, the stability of the retifanlimab product at 25 mg / mL was evaluated at different storage temperatures, agitation stress at room temperature, and freeze-thaw conditions.

[0182] In these studies, retifanlimab was formulated without antioxidants (e.g., histidine, methionine). The stability of retifanlimab was compared between pH 5 (10 mM sodium acetate buffer) and pH 6 (10 mM phosphate buffer) in the presence of sucrose, sodium chloride, and polysorbate 80 (PS80). As described below, retifanlimab precipitated and formed visible particles in pH 6 sodium phosphate buffer even in the presence of stabilizers. Retifanlimab was observed to be more stable in pH 5 acetate buffer against different stress conditions, and the presence of sucrose further stabilized the protein. Therefore, in this example, pH 5 10 mM sodium acetate buffer (3 mM glacial acetic acid, 7 mM sodium acetate) was selected as the formulation buffer for further development.

[0183] To achieve an effective osmolality suitable for intravenous (iv) administration, the non-ionic osmolyte sucrose was evaluated for its effect on retifanlimab in this exemplary pharmaceutical formulation, both alone and in combination with the ionic osmolyte sodium chloride. The addition of a surfactant, PS80, was also evaluated to determine whether it would improve stability. Based on the results of the study, 9% sucrose and 0.01% polysorbate 80 in 10 mM sodium acetate (also referred to herein as 10 mM acetate) at pH 5 was selected as the formulation buffer for further evaluation in this example. The study and results are described in further detail below.

[0184] 1.3.Evaluation of stability at 10 mg / mL protein concentration 1.3.1. Freeze-thaw research A freeze / thaw study was performed to evaluate the effect of freezing at 80°C and thawing at 25°C for five cycles on the stability of retifanlimab in the four exemplary formulations screened. Samples were analyzed initially and after one and five cycles for appearance and for subvisible particles by high accuracy liquid particle counting ("HIAC"), size exclusion high performance liquid chromatography ("SE-HPLC"), and reduced and non-reduced capillary electrophoresis-sodium dodecyl sulfate ("CE-SDS"). The appearance of the solutions was a clear, colorless solution with no visible particles in all conditions. The results of these further analyses are summarized in Table 2.

[0185] [Table 2]

[0186] The results show that significantly more subvisible particles were formed under sucrose alone conditions without the presence of PS80 after multiple freeze-thaw cycles, and the presence of PS80 significantly reduced the subvisible particles. However, in the presence of 50 mM sodium chloride, more subvisible particles were observed both initially and after five freeze-thaw cycles, with or without PS80. No significant changes in HMW species or purity with reduced and non-reduced CE-SDS were observed after five freeze / thaw cycles for any of the four formulations. From the freeze / thaw study, 9% sucrose, 0.01% PS80, 10 mM acetate, pH 5 was the most stable of the exemplary formulations for retifanlimab.

[0187] 1.3.2 Mixing Research To evaluate stability in all four exemplary formulations during screening, an agitation study was conducted at 250 rpm over 5 days at 25° C. Samples were analyzed for HIAC, SE-HPLC, reduced and non-reduced CE-SDS at T=0 (no agitation), 1, 3, and 5 days. The results are summarized in Table 3.

[0188] [Table 3]

[0189] The content of subvisible particles was higher in the sucrose alone condition (without PS80) compared to the sucrose + PS80 condition at the initial time point. The content of subvisible particles was significantly increased in the presence of sodium chloride and in the absence of PS80. The presence of PS80 in salt conditions reduced the subvisible particles, with levels being similar initially and after 5 days of shaking. No significant changes in HMW species or purity with reduced and non-reduced CE-SDS were observed after 5 days of shaking for any of the four formulations.

[0190] 1.3.3. Accelerated and stressed thermal studies Retifanlimab in the four exemplary 10 mg / mL acetate salt compositions above was stored at accelerated conditions at 25° C. and stressed conditions at 40° C. for three weeks. Samples were analyzed for appearance and SE-HPLC at the initial, 1, 2, and 3 week time points to determine stability. Appearance analysis showed that all samples were clear, colorless solutions without visible particles at all time points. SE-HPLC results for accelerated and stressed conditions are shown in Table 4.

[0191] [Table 4]

[0192] These results show that all four acetate compositions were stable over three weeks at 25° C., however, HMW species of retifanlimab formed more rapidly when stored at 40° C. in the presence of sodium chloride compared to the formulation in the absence of sodium chloride. These results demonstrate a good stability profile under stressed conditions and are further evidence that 9% sucrose, 0.01% PS80 in 10 mM acetate at pH 5 is a suitable formulation buffer for retifanlimab.

[0193] Retifanlimab in 10 mM acetate, 9% sucrose, and 0.01% PS80 was evaluated as a suitable DP composition and stored samples from the accelerated (25° C.) condition stability study were evaluated to determine if any changes in charge heterogeneity were observed after 1 month of storage. The cIEF shown in Table 5 confirms an acceptable charge variant stability profile.

[0194] [Table 5]

[0195] 1.4. Assessment of stability at selected protein concentration (25 mg / mL) Based on the planned clinical dosing for dose escalation and expansion studies during early clinical studies, and also based on the convenience of handling relatively small volumes with relatively high protein concentrations and the convenience of smaller vial sizes per given strength, the protein concentration was selected to be 25 mg / mL. Thus, the stability of the exemplary DP composition (10 mM acetate, pH 5, 9% sucrose, 0.01% polysorbate 80, pH 5.1) was evaluated at 25 mg / mL in a similar manner to the study at 10 mg / mL. The studies carried out included a freeze / thaw study (five cycles of freezing at -80°C and thawing at 25°C; Table 6), an agitation study (250 rpm, 25°C for 5 days; Table 7), and an accelerated storage study (25°C accelerated storage conditions, 1 month; Table 8).

[0196] [Table 6]

[0197] [Table 7]

[0198] [Table 8]

[0199] As shown in Tables 6-8, HIAC light obscuration analysis demonstrated that the formulation had no significant increase in subvisible particles. Furthermore, no significant changes in HMW species were observed by SE-HPLC, no significant changes in fragmentation by non-reduced and reduced CE-SDS, and no significant changes in charge heterogeneity by cIEF. These results demonstrate acceptable stability of 25 mg / mL retifanlimab in the formulation.

[0200] Retifanlimab DP compositions were formulated at 25 mg / mL of retifanlimab in 10 mM sodium acetate (0.95 mg / mL sodium acetate trihydrate, 0.18 mg / mL glacial acetic acid), 90 mg / mL sucrose, and 0.1 mg / mL polysorbate 80, pH 5.1. The ingredients of selected retifanlimab DP compositions are shown below in Table 9. Retifanlimab DP compositions were provided in 10 mL or 20 mL type 1 borosilicate vials as shown in Table 9: 250 mg / 10 mL (10 mL vial), 375 mg / 15 mL (20 mL vial), or 500 mg / 20 mL (20 mL vial).

[0201] [Table 9]

[0202] 1.5. Characterization and robustness study of retifanlimab compositions using experimental design Next, a Design of Experiments (DoE) study was conducted to verify the robustness of the exemplary Retifanlimab DP composition for use and to develop a control strategy for the Retifanlimab DP composition manufacturing process. The DoE study was used to demonstrate the robustness of the exemplary Retifanlimab DP composition over a range of composition parameters beyond the target composition, and the Retifanlimab DP composition was evaluated at the recommended storage temperature of 2-8°C for 24 months and at an accelerated temperature condition of 25°C for 6 months.

[0203] A range of five compositional parameters was investigated as shown in Tables 10 and 11. In addition to all formulations (F1-F16) designed for the DoE study, the center point formulations (F9 and F16) and low protein concentration (21 mg / mL) formulations (F1, F4, F6, F7, F12, and F15) and high protein concentration (29 mg / mL) formulations (F2, F3, F5, F8, F13, and F14) were evaluated. All formulation parameters evaluated in this study were intended to exceed the upper and lower limits of their respective concentrations during manufacturing. For example, the range of PS80 varies from 0.02 mg / mL to 0.53 mg / mL. In this particular case, the values ​​tested were significantly wider than the desired range during manufacturing. In the DoE study, pH was evaluated within the range of pH 4.5 to pH 5.7. The protein concentration range evaluated was within the target ± 15%.

[0204] [Table 10]

[0205] [Table 11]

[0206] The designated formulations were prepared by tangential flow filtration and product stability was evaluated at the intended long-term storage conditions (2-8°C) for up to 48 months and at accelerated conditions (25°C) for 6 months (see Example 3).

[0207] At each time point, the effect of formulation variables on the drug product was evaluated using the following assays: appearance, size-exclusion high performance chromatography (SE-HPLC), capillary isoelectric focusing (cIEF), protein concentration (Abs 280 ), invisible particle count (HIAC), pH, and PD-1 binding ELISA.

[0208] The statistical significance of each formulation variable on product quality was assessed by performing a multivariate analysis (MVA). A predictive profiler was generated to understand the relationship between individual formulation parameters and product quality, and the importance of each formulation factor.

[0209] 1.5.1. Results from formulation robustness and stability studies using experimental design The experimental design and statistical analysis provide an understanding of the relationship between the product quality attributes and the selected formulation parameters and storage conditions. The predictive profilers for the formulation samples stored at 5±3°C and 25°C for 6 months are shown in Figure 1. The results from the formulation robustness and stability study for the different product quality attributes are discussed in the following sections.

[0210] 1.5.1.1. Results of % Monomer, % HMW, and % LMW Species Monitored by SE-HPLC SE-HPLC studies demonstrated that formulated samples stored at 2-8°C were stable over 6 months for both %monomer (M) and %HMW, with data trends indicating no significant changes in stability. No decrease in monomer content greater than 0.3% was detected after 6 months of storage at 2-8°C, regardless of pH level. Under accelerated storage conditions at 25°C, monomer purity decreased by 0.1-2.6% over 6 months. Correspondingly, %HMW increased by 0.1-2.2% over 6 months for all 16 formulations.

[0211] These stability data demonstrate that variations in pH, excipient conditions, and buffer conditions of the retifanlimab formulation within the ranges evaluated do not result in significant changes in % monomer, % HMW, and % LMW species as a function of storage time at the recommended storage temperatures of 2-8°C.

[0212] 1.5.1.2.cChanges in charge heterogeneity monitored by IEF Charge heterogeneity of all exemplary formulations was monitored by measuring acidic variants ("AV"), main charge peaks ("MCP"), and basic variants ("BV") by cIEF.

[0213] Within the range of excipients and pH conditions tested, storage at the expected temperatures (2-8° C.) resulted in only minor changes in charge heterogeneity, and no statistically significant effect of any of the formulation parameters on the charge variants of formulations stored at 2-8° C. More significant changes were observed after 6 months of storage at 25° C. pH and PS80 have a statistically significant effect on the charge heterogeneity of the exemplary formulations at 25° C.

[0214] At 2-8°C, only a small increase in AV was detected after 6 months, this increase being less than 1.2%. After 6 months of storage at 25°C, AV levels increased by an average of 13.2% and 14.4% for the pH 5.7 and pH 4.5 formulations, respectively. Furthermore, a 12.8% increase in AV was observed for the pH 5.1 target formulation.

[0215] Correspondingly, after 6 months of storage under long-term storage conditions (2–8 °C), slight variations in cIEF MCP results were observed for all 16 formulations. The drop in MCP levels was 0.6% or less. However, under accelerated conditions at 25 °C, MCP levels decreased by up to 14.5%.

[0216] A slight drop in BV was detected between 2 and 8°C, the drop being less than 0.9%. In samples stored at 25°C for up to 6 months, the BV levels changed more significantly, the drop being less than 4.9%.

[0217] The results of this stability study demonstrated that pH 5.1 ± 0.3 is the pH range where minimal degradation occurs at the recommended storage conditions of 2-8 °C. These formulation robustness and stability studies demonstrate that the pH and buffer conditions of the retifanlimab formulation excipients induce only minor changes in the charge heterogeneity profile within the range evaluated during storage at the recommended storage temperatures of 2-8 °C. These minor changes in the charge heterogeneity variants did not translate into significant changes in the relative potency of retifanlimab.

[0218] 1.5.1.3. Appearance and non-visible particles The appearance of all formulations in terms of clarity and visible particles was determined. Formulation F13 in particular showed a strong milky color with precipitation compared to the other formulations, especially for samples stored at 2-8°C. Without wishing to be bound by any theory, such physical instability is attributed to the combined effect of the worst-case marginal individual formulation parameters, i.e., the lowest PS80 content, the lowest sucrose content, and the highest pH, combined with the highest protein concentration causing protein precipitation. Based on the appearance results and the subvisible particle data, the evaluated PS80 levels were effective in stabilizing the retifanlimab DP composition against particle formation.

[0219] 1.6. Overview of formulation development Based on the above formulation development studies, the exemplary antioxidant-free DP composition (25 mg / mL retifanlimab, 10 mM acetate, 9% sucrose, and 0.01% PS80, pH 5.1) provided good stability and resulted in an optimal composition of retifanlimab at a concentration of 25 mg / mL. Higher retifanlimab concentrations are also contemplated and supported by these studies. As a subsequent step, the formulation robustness study aimed to establish the robustness of the exemplary retifanlimab DP composition by varying a series of formulation parameters. Consistent with the historical stability profile of retifanlimab DP, more pronounced chemical degradation effects were observed under accelerated storage conditions with elevated temperature (25°C) compared to long-term storage conditions (2-8°C). At 2-8°C, pH was the only formulation parameter with a statistically significant effect on product stability, although the observed changes were not of practical importance. This is because the actual values ​​are well within the specifications for the product attributes and, in some cases, within the range of assay variability.

[0220] Under accelerated storage conditions (25°C), different pH and PS80 levels affected aggregate formation over time (SE-HPLC) and charge heterogeneity (cIEF). It was also observed that ionic strength and protein concentration affected basic variants and HMW%, respectively. However, the actual values ​​of all these quality attributes were still well within the specifications.

[0221] In summary, the data collected from this formulation robustness study supports the specifications of pH, PS80, sucrose, and buffer salt concentrations for the DP composition. In contrast to other antibody compositions described, the DP composition provides a stable composition of retifanlimab without the need for added antioxidants.

[0222] 1.7. Method of Supplying Retifanlimab Composition in Vials The retifanlimab DP composition is provided as a sterile, buffered aqueous solution in Type I borosilicate 10 mL (250 mg / vial) or 20 mL (375 mg / vial and 500 mg / vial) glass vials conforming to USP and Ph.Eur., capped with 20 mm FluroTec® and B2-40 coated butyl rubber stoppers. The components of the retifanlimab DP composition are provided in Table 9. The nominal contents of each retifanlimab DP composition vial were 10 mL, 15 mL, or 20 mL. Each vial was overfilled with 0.6 mL of liquid. The overfill was included to ensure sufficient volume to withdraw 10 mL (250 mg), 15 mL (375 mg), and 20 mL (500 mg) of retifanlimab for dose delivery. The target fill volume, deliverable volume, and vial / syringe hold-up volume were determined by extractable volume testing. The retifanlimab DP composition is a colorless to light yellow, clear to slightly opalescent solution, substantially free of visible particles. The retifanlimab DP composition provided as described in this section was used in the dosage compatibility study, as well as the long-term and accelerated stability studies described below.

[0223] Example 2 Compatibility study of IV administration of retifanlimab Retifanlimab DP compositions are available in single dose vials (see Example 1.7) and are administered as intravenous (IV) infusions after dilution in saline (0.9% sodium chloride injection, USP) or D5W (5% dextrose in water, USP). The dilution is calculated based on the amount to be administered, e.g., a flat dose of 375 mg (for weight-based doses, it will be understood that the patient's weight and dose are used to calculate the amount). To prepare for infusion, dilution of the retifanlimab solution is performed in a commercially available IV administration bag containing saline or D5W. The infusion solution is administered to the patient from a dose-prepared 0.9% sodium chloride IV bag or D5W IV bag using a commercially available IV pump and IV administration tubing set. As described in further detail below, stability and compatibility studies were performed by dilution of prepared doses of retifanlimab and storage at 25°C (up to 6 hours) and 2-8°C for up to 24 hours, as well as IV administration of retifanlimab using unfiltered and filtered IV infusion sets over 30 and 60 minute IV infusion periods.

[0224] In the first compatibility study, the retifanlimab DP composition was diluted in IV bags of the same composition as those commonly used in the clinic, i.e., polyolefin copolymer (polypropylene and polyethylene), PVC containing DEHP, polyamide-coated polyolefin, and EVA, which were kept at 25°C. The dilution scheme of the test IV bags followed a bracketing approach and multiple drug concentrations (1.4 mg / mL, 4.5 mg / mL, and 10 mg / mL) were tested in each IV bag type, which represent high and low dose concentrations. The structural integrity of retifanlimab was maintained at all conditions and time points, as assessed by size exclusion chromatography (SE-HPLC) and protein concentration recovery. These studies support the stability of retifanlimab and its suitability for clinical administration when the pharmaceutical composition of the present disclosure is diluted in 0.9% sodium chloride or D5W in PVC, polyolefin, and polyolefin copolymer IV bags.

[0225] 2.1. Overview of compatibility study using retifanlimab One compatibility study of retifanlimab was conducted using saline as the diluent. A second compatibility study of retifanlimab was conducted using D5W as the diluent. A third compatibility study was conducted to implement a filtered extension set to reduce subvisible proteinaceous particles. These studies were conducted to demonstrate the compatibility and stability of the exemplary retifanlimab DP composition with IV infusion sets with pore size filters of 0.2 μm, 5 μm, or 15 μm. A fourth study was conducted to evaluate IV solution temperature cycling and shaking studies on the short-term stability of the exemplary retifanlimab dosing solution preparation to simulate the transportation of prepared IV bags from a clinical pharmacy to a site for administration subordinate thereto.

[0226] The types of IV bags, infusion sets, and filters tested are summarized in Tables 12-14.

[0227] [Table 12]

[0228] [Table 13]

[0229] [Table 14]

[0230] 2.2.Evaluation of compatibility of retifanlimab with 0.9% saline The compatibility of retifanlimab in an exemplary retifanlimab DP composition with saline (at concentrations of 1.4 mg / mL, 4.5 mg / mL, and 10 mg / mL) with different sizes of IV bags (100 mL and 250 mL) made of different types of materials (Table 12), different administration sets (Table 13), and with in-line 0.2 μm PES membrane sterile filters was evaluated.

[0231] Study design Retifanlimab in the exemplary retifanlimab DP composition was diluted with saline to concentrations of 1.4 mg / mL, 4.5 mg / mL, and 10 mg / mL in 100 mL or 250 mL IV bags containing saline (Table 12). A 250 mL IV bag was used for the retifanlimab IV solution preparation with a concentration of 1.4 mg / mL, and a 100 mL bag was used for the concentrations of 4.5 mg / mL and 10 mg / mL. The IV bags were then stored at room temperature for 6 hours and at 2-8°C for 24 hours. All bags stored at 2-8°C were followed by a 4-hour room temperature equilibration period. Samples were collected from each bag at dose preparation completion (T=0) and after the completion of the incubation period (pre-infusion samples).

[0232] After completion of the incubation period, the bag was connected to a corresponding IV administration set equipped with an in-line filter (a low protein binding 0.2 μm PES membrane filter). The entire contents of the bag were infused over 25 minutes (allowing for a "worst-case scenario" of a targeted infusion time of 30 minutes) and a "post-infusion" sample was collected and tested.

[0233] 2.2.2.Results The results of these studies demonstrate that no significant changes were observed in protein concentration, pH, appearance and size distribution (SE-HPLC), charge distribution (cIEF), and potency by ELISA for all groups tested. The % protein recovery of all concentrations of retifanlimab after 30 minute infusion following storage of IV bags under two conditions: incubation at room temperature for 6 hours and at refrigerated temperature for 24 hours showed no significant changes relative to the protein concentration at T=0 for each condition.

[0234] Infusion solutions in saline had increased subvisible particles at pre-infusion time points. However, subvisible particles could be reduced with an in-line filter infusion set, as shown by the post-infusion subvisible particle results. Representative results of an in-use compatibility study of low dose (1.4 mg / mL; Table 15) and high dose (10 mg / mL; Table 16) retifanlimab using PVC+DEHP IV bags and PE infusion sets with saline as the dosing mixture are shown below.

[0235] [Table 15]

[0236] [Table 16]

[0237] 2.3.Evaluation of compatibility of D5W with retifanlimab The compatibility of retifanlimab in an exemplary retifanlimab DP composition with D5W (at concentrations of 1.4 mg / mL, 4.5 mg / mL, and 10 mg / mL) with different sizes of IV bags (100 mL and 250 mL) made of different types of materials (Table 12), different administration sets (Table 13), and with an in-line 0.2 μm PES membrane sterile filter was evaluated.

[0238] Study design Retifanlimab was diluted with D5W to concentrations of 1.4 mg / mL, 4.5 mg / mL, and 10 mg / mL in 100 mL or 250 mL IV bags containing D5W (Table 12). A 250 mL IV bag was used for the 1.4 mg / mL retifanlimab IV solution preparation, and a 100 mL bag was used for the 4.5 mg / mL and 10 mg / mL concentrations. The IV bags were then stored at room temperature for 6 hours and at 2-8°C for 24 hours. All bags stored at 2-8°C were followed by a 4 hour room temperature equilibration period. Samples were collected from each bag at dose preparation completion (T=0) and after the completion of the incubation period (pre-infusion samples).

[0239] After completion of the incubation period, the bag was connected to a corresponding IV administration set equipped with an in-line filter (a low protein binding 0.2 μm PES membrane filter). The entire contents of the bag were infused over 25 minutes (allowing for a "worst-case scenario" of a targeted infusion time of 30 minutes) and a "post-infusion" sample was collected and tested.

[0240] 2.3.2.Results The results of these studies demonstrate that no significant changes were observed in protein concentration, pH, appearance and size distribution (SE-HPLC), charge distribution (cIEF), and potency by ELISA for all groups tested. The % protein recovery of all concentrations of retifanlimab after 30 minute infusion following storage of IV bags under two conditions: incubation at room temperature for 6 hours and at refrigerated temperature for 24 hours showed no significant changes relative to the protein concentration at T=0 for each condition.

[0241] Infusion solutions containing D5W formed less subvisible particles at pre-infusion time points than saline as an admixture. Additionally, subvisible particles could be reduced with an in-line filter infusion set, as shown by the post-infusion subvisible particle results. Representative results of an in-use compatibility study of low dose (1.4 mg / mL; Table 17) and high dose (10 mg / mL; Table 18) retifanlimab with D5W as the administration admixture using PVC+DEHP IV bags and PE infusion sets are shown below.

[0242] [Table 17]

[0243] [Table 18]

[0244] 2.4. Evaluation of in-use compatibility of Retifanlimab DP compositions with different types of filter membranes and pore sizes In an initial in-use compatibility study of an exemplary retifanlimab DP composition: some visible and subvisible particulates were observed in saline by visual inspection only after incubation at two storage conditions: 25°C for 6 hours and 2-8°C for 24 hours. Characterization of the visible particulates by Raman spectroscopy confirmed the proteinaceous nature of the particles. An IV infusion set equipped with a 0.2 μm low protein binding in-line filter was able to remove visible particulates and reduce subvisible particulates in the post-infusion sample. A more comprehensive study was performed to evaluate the suitability and performance of filters of different membrane materials (polyvinylidene fluoride (PVDF), polyethersulfone (PES), and cellulose acetate (CA)) and sizes (0.2 μm, 5 μm, and 15 μm)) for removing proteinaceous subvisible and visible particles.

[0245] Study design Three concentrations of retifanlimab doses (1.4 mg / mL, 4.5 mg / mL, and 10 mg / mL) diluted in saline were prepared from the exemplary retifanlimab DP composition. Visible particle formation was observed more with saline as an admixture than with D5W, so only saline was used to prepare the IV solution. After completion of dose preparation, the IV bags were stored at 2-8°C overnight and allowed to equilibrate for 4 hours at room temperature the following day. This represents a "worst case scenario" for particle generation. Samples were taken and tested at the time of dose preparation (T=0), after T=24 hours at 2-8°C followed by a 4 hour equilibration period at room temperature (post-hold), and from the final dispense pool after the simulated infusion ("post-infusion").

[0246] 2.4.2.Results All add-on filters of all sizes were able to reduce subvisible particles. Overall, there was no impact on product quality for post-injection samples for all materials tested when in-line or add-on filters were used after 6 hours of storage at room temperature and 24 hours at 2-8°C. Representative results from an in-use compatibility study with 0.2 μm polyvinylidene fluoride (PVDF) and cellulose acetate (CA) filters for low dose (1.4 mg / mL; Table 19) and high dose (10 mg / mL; Table 20) retifanlimab in saline are shown below.

[0247] [Table 19]

[0248] [Table 20]

[0249] 2.5. Temperature Cycling and Shaking Studies of IV Administration Bag Preparations The short-term stability of an exemplary retifanlimab dosing solution formulation was evaluated by temperature cycling and shaking studies of the IV dosing solution to simulate the transportation of prepared IV bags from the clinical pharmacy to the sub-site for administration. Two concentration levels were evaluated, 1.4 mg / mL (low dose) and 10 mg / mL (high dose), to capture both ends of the concentration range of retifanlimab after dilution in the IV bag. Normal saline was selected as the diluent for this study. Both high and low concentration retifanlimab IV preparations were prepared in the diluent and held at room temperature for 6 hours, then held at 2-8°C overnight, and held at room temperature for an additional 6 hours. This represents a possible "worst case" holding time scenario for suitability at time of use. After this temperature cycling, the samples were shaken to simulate the shaking that may occur during transportation of the IV bag to the site of administration.

[0250] Study design The concentrations of the solutions for IV administration were prepared by using an exemplary 375 mg retifanlimab DP composition in a 250 mL saline IV bag (low dose) and an exemplary 1,000 mg retifanlimab DP composition in a 100 mL saline IV bag (high dose). This range covers the effective dose of retifanlimab, 500 mg Q4W. The IV bag was prepared by removing 15 mL (for the low concentration of 1.4 mg / mL) or 50 mL (for the high concentration of 10 mg / mL) of saline from the bag before adding the retifanlimab DP composition. The detailed dose preparation and final retifanlimab concentration in the IV bag are listed in Table 21 below.

[0251] [Table 21]

[0252] Upon completion of dose preparation, a 15 mL sample was collected from the bag into a 30 mL glycol modified polyethylene terephthalate ("PETG") bottle (T=0). After sample collection, the bag was stored at room temperature for 6 hours and then held at 2-8°C overnight, followed by a second equilibration period at room temperature for 6 hours.

[0253] After temperature cycling, a second 15 mL sample was withdrawn from the bag, which was then placed on an orbital shaker programmed to perform 60 minutes of shaking at 100 RPM, which was applied to simulate the transportation of prepared IV bags from a clinical pharmacy to the associated administration site.

[0254] After shaking was completed, samples were removed directly from the bag for analytical testing. Samples were then collected after infusion through an administration set containing a 0.2 μm in-line filter. The study design is described in Table 22. Table 23 lists the analytical testing methods performed at different stages of this study.

[0255] [Table 22]

[0256] [Table 23]

[0257] 2.5.2.Results The results of the temperature cycling and shaking study of the IV bags are shown in Table 24. In summary, the pH and concentration of the solutions did not change after temperature cycling and shaking for both doses as expected. The concentration of the post-injection samples remained consistent for both doses. The appearance results confirmed the presence of visible particles in the post-shaking samples. These observations were confirmed by the HIAC results which showed a significant increase in subvisible particles both after temperature cycling and after shaking. Injection of the IV bags through an administration set containing a 0.2 μm in-line filter successfully reduced the number of subvisible particles. Reverse Osmosis Deionized ("RODI") water blanks showed significant numbers of particles 2 μm or larger in the HIAC, so the reported sample results have been adjusted to subtract the counts in the RODI blank. The SE-HPLC results showed no change in the percentage of monomer peak and % HMW species for both doses. cIEF results showed similar charge profiles for samples for both doses and remained within the acceptance criteria. Furthermore, results for potency of samples at T=0 and after shaking were consistent and remained within the acceptance criteria for both doses.

[0258] [Table 24]

[0259] 2.6. Microbial challenge testing To ensure patient safety in case of accidental contamination during handling during clinical use, a microbial challenge test was performed during preparation of the diluted exemplary retifanlimab solution. In this study, the exemplary retifanlimab DP composition was diluted to two concentration levels, 1.4 mg / mL and 10 mg / mL, in saline or D5W to capture both ends of the concentration range of retifanlimab after dilution in the IV bag. The microbial challenge test was performed in duplicate by inoculating the diluted retifanlimab preparation with the following five microorganisms at approximately 10-100 CFU / mL, as well as typical skin contaminants (Table 25).

[0260] [Table 25]

[0261] The suitability of the microbial enumeration method (membrane filtration method) in combination with retifanlimab and the microorganisms was demonstrated prior to the implementation of the microbial challenge test. The absence of microbial growth was defined as a 0.5 log decrease in CFU / mL compared to the value at T0. 10 was defined as an increase in

[0262] Microbial growth was evaluated under two different storage conditions, each with a separate set of diluted retifanlimab preparations. In the first condition, the IV bags containing the diluted retifanlimab were stored at 2-8°C for 48 hours followed immediately by storage at room temperature (20-25°C) for 12 hours, for a total storage time of 60 hours. In the other condition, the prepared IV bags were stored at room temperature (20-25°C) for 16 hours. At each time point, the diluted retifanlimab preparations were evaluated for bacteriostatic / fungistatic properties and relative resistance to microbial growth. Test results for retifanlimab solutions diluted in saline at 1.4 mg / mL (Tables 26 and 27) and 10 mg / mL (Tables 28 and 29) for samples stored at 2-8°C and then incubated at room temperature are shown below. For retifanlimab DP compositions diluted in D5W, the test results are summarized in Tables 30 and 31 (1.4 mg / mL) and Tables 32 and 33 (10 mg / mL).

[0263] [Table 26]

[0264] [Table 27]

[0265] [Table 28]

[0266] [Table 29]

[0267] [Table 30]

[0268] [Table 31]

[0269] [Table 32]

[0270] [Table 33]

[0271] For studies conducted at room temperature (20-25°C), test results for retifanlimab solutions diluted in saline are summarized in Table 34 (1.4 mg / mL) and Table 35 (10 mg / mL). For retifanlimab compositions diluted in D5W, test results are summarized in Table 36 (1.4 mg / mL) and Table 37 (10 mg / mL).

[0272] [Table 34]

[0273] [Table 35]

[0274] [Table 36]

[0275] [Table 37]

[0276] For the retifanlimab DP composition diluted in 0.9% saline at the two concentrations above, the increase in microbial count (i.e., 0.5 log compared to the value at T=0) was 10 No increase in CFU / mL was observed for any of the six organisms tested at both temperature conditions during the period tested. For the retifanlimab DP composition diluted in D5W, none of the tested microorganisms showed growth over time in any of the test samples at both concentration levels and both storage conditions. Some of the retifanlimab dilutions showed a decrease in the microbial count of certain microorganisms over time. This phenomenon was more pronounced for samples inoculated with two gram-positive bacteria, namely Staphylococcus aureus and Staphylococcus epidermidis. In summary, none of the combinations of diluted retifanlimab solutions in either 0.9% saline or D5W showed an increase in the microbial count over time.

[0277] 2.7. Conclusions of the study on suitability for administration of retifanlimab The disclosed retifanlimab pharmaceutical composition was shown to be compatible with saline and D5W solutions in multiple IV bags of different constituent materials at concentrations of 1.4 mg / mL, 4.5 mg / mL, and 10 mg / mL, and with all the various administration sets used. These results support a 30 minute retifanlimab IV solution administration time and storage of the IV bag preparation for up to 6 hours at room temperature and 24 hours at 2-8°C. Furthermore, all tested in-line or add-on filters of different materials and pore sizes were compatible with retifanlimab.

[0278] The results of the temperature cycling and shaking studies show that at both the 1.4 mg / mL and 10 mg / mL concentrations, under "worst case" simulated storage and shaking conditions, an increase in visible and subvisible particles (>= 10 and 25 μm) was observed, with no other effects on product quality. However, after injection through an in-line filter, no visible particles remained and subvisible particles were significantly reduced.

[0279] To ensure patient safety during handling at the time of use, a microbial challenge study was performed during preparation of Retifanlimab IV infusion solution. To reflect the possibility of clinical storage of the IV preparation in the refrigerator and at room temperature, Retifanlimab IV preparation diluted in saline and 5% dextrose solution was stored under two different conditions: storage at 2-8°C for 48 hours followed by storage at room temperature for another 12 hours; and storage at room temperature for 12 hours. The results of the microbial challenge study also support the proposed storage of Retifanlimab IV bags at room temperature for up to 6 hours and at 2-8°C for 24 hours.

[0280] Example 3 Long-term and accelerated stability studies Long-term and accelerated stability studies of exemplary retifanlimab DP compositions in stoppered 10 mL or 20 mL glass vials were conducted. Stability was evaluated for retifanlimab DP compositions stored at recommended conditions of 2-8° C. for up to 60 months and for retifanlimab DP compositions stored at accelerated conditions of 25° C. for up to 6 months.

[0281] Experimental Design A summary of the studies used and typical evaluation intervals at storage conditions of 2-8° C. and 25° C. are provided in Tables 38A and 38B, respectively. These studies were performed on 12 different lots of the exemplary retifanlimab DP composition. The majority of the studies were performed with inverted vials and at least one was performed with an upright vial.

[0282] [Table 38]

[0283] [Table 39]

[0284] 3.2.Results The results of all tests on representative lots stored at 2-8°C for 60 months and at 25°C for 6 months are shown in Tables 39A-39B and 40, respectively. Further details regarding assay potency, purity, and protein stability (monomer and acidic and basic variants) are provided in the summary below.

[0285] [Table 40]

[0286] [Table 41]

[0287] [Table 42]

[0288] Stability data for all DP lots investigated are within acceptable limits over 60 months at the intended long-term storage conditions of 2-8 °C. A slight decrease in purity was observed by the purity methods SE-HPLC, reduced CE-LDS, and non-reduced CE-LDS. Heterogeneity by cIEF also had a slight decrease in the main peak with a corresponding increase in the acidic variant. No further changes beyond analytical procedure variability were observed for other monitored parameters.

[0289] At accelerated storage conditions of 25 ± 2 °C, a slight decrease in purity was observed by the purity methods SE-HPLC (≦1%), reduced CE-LDS (≦1%), and non-reduced CE-LDS (≦2.5%). These changes in purity under accelerated conditions were not unexpected for the protein, and the results were well within acceptable limits. Heterogeneity by cIEF showed a moderate increase in acidic variants (up to 17.5% increase). The acidic variants contain mainly deamidated products. No changes beyond the variability of the analytical procedure were observed for any of the other parameters monitored, demonstrating the robust stability of retifanlimab DP.

[0290] 3.3. Conclusions regarding stability The above analysis of quantitative data obtained from the stability demonstration method for multiple lots supports a shelf life of at least 24 months for the retifanlimab pharmaceutical composition of the present disclosure at recommended storage conditions of 2-8° C. The representative stability data presented in Tables 39A-39B and Table 40 also show that all other tests, both qualitative and semi-quantitative or non-quantitative, remained within acceptable limits over at least 24 months, supporting a shelf life of at least about 24 months, with an upper limit of at least about 36 to at least about 60 months.

[0291] Example 4 Materials and Methods 4.1.A 280 Protein concentration by The protein concentration of retifanlimab was determined by a SoloVPE system (SoloVPE Variable Pathlength UV System from C Technologies, Inc.). The SoloVPE system employs the Slope Spectroscopy method, which is based on the Beer-Lambert law and the slope obtained from linear regression of absorbance measurements at 280 nm performed at multiple path lengths. The protein concentration was calculated using the following Slope Spectroscopy equation: Protein concentration (mg / mL)=c=M / α where c is the concentration, M is the slope of the regression line, and α is the extinction coefficient calculated based on the amino acid sequence of retifanlimab [1.43 (mg / mL)]. -1 cm -1 ].

[0292] 4.2. Invisible Particles by HIAC Liquid Particle Counting USP <788> and Ph.Eur.2.9.19 were used to detect, size, and count subvisible particulate matter in the formulation. An electronic liquid particle counting system with a light obscuration sensor was employed. Particles are counted in three size ranges using an electronic liquid particle counting system with a light obscuration sensor (HIAC): ≥ 2 μm (characterization information only), ≥ 10 μm, and ≥ 25 μm. Ten vials (10 mL / vial) of the formulation are pooled for analysis.

[0293] 4.3.Appearance Appearance was assessed visually in front of both white and black backgrounds under visible light meeting the minimum intensity requirements according to Ph.Eur. 2.2.1 and 2.2.2. Aliquots of samples were evaluated in clear glass vials. Attributes examined included solution color and solution clarity. The degree of coloration was determined using Ph.Eur. certified color standards. The degree of clarity was determined using Ph.Eur. certified reference suspension standards.

[0294] 4.1.pH Test The pH of the solution was measured according to the official method [USP <791> The pH was measured potentiometrically using a calibrated pH meter in accordance with [Russian Pharmacopoeia, Ph.Eur.2.2.3]. Prior to testing the samples, the pH meter was three-point calibrated using certified pH standards, starting with a pH 7 buffer standard, then a pH 4 buffer standard, and then a pH 10 buffer standard. Following calibration, the suitability of the system was checked using two certified pH buffers, pH 5 and pH 8.

[0295] 4.4. Monomer Purity by Size Exclusion High Performance Liquid Chromatography (SE-HPLC) Size-exclusion high performance liquid chromatography (SE-HPLC) was used as a measure of product purity and to measure impurities, especially product aggregates. The assay includes a retifanlimab reference standard as a control for the identity of the monomer peak and suitability of the system. Samples are injected onto a size-exclusion HPLC column and eluted isocratically with sodium phosphate / sodium sulfate buffer. Eluted protein was detected using ultraviolet (UV) absorbance at 280 nm. The reportable result was product purity, calculated as the area percent of the product monomer peak (compared to all peaks minus excipient peaks). Also reported were the total percent of all species with an apparent molecular weight greater than the monomer (referred to as high molecular weight species, or HMW), the percent of dimers (a potential component of the HMW species), and the total percent of all species with an apparent molecular weight less than the monomer (referred to as low molecular weight species, or LMW).

[0296] 4.5. Charge Heterogeneity and Identity by cIEF The charge heterogeneity and identity of retifanlimab were assessed by capillary isoelectric focusing (cIEF). cIEF was performed using an iCE3 system (ProteinSimple) equipped with an Alcott 720NV autosampler. Retifanlimab reference standards and test article samples containing carrier ampholytes and pI markers were prepared and loaded into a capillary cartridge for analysis. Electrolyte tanks at each end of the capillary were filled with anolyte and catholyte. A voltage was applied to focus the sample at the pI of the sample. A camera took UV light absorption images of the entire capillary column every 30 seconds, allowing real-time monitoring of the focusing step described above. The resulting separation pattern images were captured and analyzed with the chromatography data system software. The electrophoretic profiles of the test articles were compared to those of the reference standards. Reportable results from this assay were the average main charge peak % area, the average acidic variant % area, and the average basic variant % area of ​​duplicate preparations.

[0297] To confirm identity where necessary, within a given sample set, the pI of the major peak of the test article should be within 0.5 pI units of the pI of the major peak of the retifanlimab reference standard, and the profile of the test article should be qualitatively comparable to that of the reference standard.

[0298] 4.6. Purity by reduced CE-LDS Lithium dodecyl sulfate capillary electrophoresis (CE-LDS) provided quantitative information on product purity and qualitative information on the nature of impurities, adducts, product fragments, and covalent species. Samples were denatured and reduced by heating in LDS sample buffer containing the reducing agent 2-mercaptoethanol (βME). Samples were then electrophoresed using a Sciex (ABSciex, Beckman) PA800 / PA800 Plus instrument. Test articles and reference standard samples are loaded into capillary cartridges and product purity is determined by UV detection. After electrophoresis was completed, data was analyzed using electrophoresis software. The reportable result for the test article was % purity, defined as the sum of the percentages of peaks corresponding to the light chain (LC) and heavy chain (HC), which was recorded to the nearest 0.1%.

[0299] 4.7. Purity by non-reduced CE-LDS Non-reduced lithium dodecyl sulfate capillary electrophoresis (CE-LDS) provided quantitative information on product purity and qualitative information on the nature of impurities, adducts, product fragments, and covalent species. Samples were mixed with LDS sample buffer (without reducing agent) and heated. Samples were then electrophoresed using a Sciex (ABSciex, Beckman) PA800 / PA800 Plus instrument. Test articles and reference standard samples were loaded into capillary cartridges and product purity was determined by UV detector. After electrophoresis was completed, data was analyzed using electrophoresis software. Reportable results for test articles were % purity (=% of intact retifanlimab relative to all peaks detected), which was recorded to the nearest 0.1%.

[0300] 4.8. Potency by PD-1 Binding ELISA Potency was assessed using an indirect enzyme-linked immunosorbent assay (ELISA) to quantify the binding activity of retifanlimab to PD-1. Recombinant human PD-1 was coated onto the solid phase (96-well assay plate). Retifanlimab samples were allowed to bind to the immobilized PD-1. Dilution series of the test article and retifanlimab reference standard were tested in this manner to generate a dose-response curve. Detection of retifanlimab bound to immobilized PD-1 was achieved using an alkaline phosphatase (AP)-conjugated anti-human kappa antibody (aHuk-AP) that binds to retifanlimab. Quantitation of bound probe antibody aHuk-AP was achieved by addition of a colorimetric AP substrate. Oxidation of the added AP substrate by the bound AP yielded a colored product that was measured spectrophotometrically. The absorbance response detected is proportional to the amount of retifanlimab present. Data were fitted to a constrained four-parameter logistic model to evaluate absorbance as a function of retifanlimab concentration. Reportable results, i.e., PD-1 potency of test articles relative to the retifanlimab reference standard, were calculated using the following formula: Relative potency = 100% × EC 50 INCMGA00012 Reference Standard / EC 50 Test Article

[0301] 4.9. Potency and Identity by PD-1 Blockade ELISA The identity and potency of retifanlimab samples were assessed using PD-1 receptor binding and signaling bioassays. The potency of retifanlimab antibodies was determined by their ability to block the binding of the PD-1 receptor (presented on Jurkat cells) to the PD-L1 ligand (presented on U2OS cells) using a PD-1 blocking bioassay. Blocking this interaction prevents the SHP1 recruitment pathway that initiates in the absence of PD-1 antibodies and generates a chemiluminescent signal in Jurkat engineered cells. Disruption of the PD-1 / PD-L1 complex, and therefore SHP1 recruitment, prevents the formation of active galactosidase enzyme, which can be directly quantified by inhibition of the downstream chemiluminescent signal and can be measured with a luminescence reader. The data were fitted to a constrained four-parameter logistic model to assess luminescence as a function of the log concentration of retifanlimab. The reportable result, i.e., the PD-1 potency of the test article relative to the retifanlimab reference standard, was calculated using the following formula: Relative potency = 100% × EC 50 Retifanlimab Reference Standard / EC 50 Test Article

[0302] 4.10. Microbial challenge testing Retifanlimab was diluted to two concentration levels, 10 mg / mL and 1.4 mg / mL, with 0.9% saline or 5% dextrose in water to capture both ends of the concentration range of retifanlimab after dilution in the IV bag. Microbial challenge studies were performed using five USP <51> and typical skin contaminants were inoculated into the diluted retifanlimab preparations in duplicate.

[0303] The suitability of the microbial enumeration method (membrane filtration method) in combination with the retifanlimab DP and microorganisms was demonstrated prior to the performance of the microbial challenge study. The absence of microbial growth was consistent with USP <51> According to the above, 0.5 log of CFU / mL compared to the value at T0 10 was defined as an increase in

[0304] The study was conducted at the recommended storage temperature and for twice the recommended storage period. Thus, the diluted retifanlimab preparations were first stored at 2-8°C for 48 hours and then immediately stored at room temperature (20-25°C) for 12 hours, for a total storage time of 60 hours. At each time point, the diluted retifanlimab preparations were evaluated for bacteriostatic / fungistatic activity and relative resistance to microbial growth.

[0305] Osmolality Osmolality can be calculated from the USP <785> The measurements were performed using a freezing point depression osmometer using the method defined in [Ph.Eur.2.2.35]. NIST traceable standards were used to calibrate each measurement. The suitability of the system was determined prior to the measurement of the test articles by measuring the NIST traceable standards.

[0306] All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

[0307] The present disclosure is not limited with respect to the specific embodiments described in this application. As will be apparent to those skilled in the art, numerous modifications and variations can be made without departing from the spirit and scope of the present disclosure. In addition to those recited in this disclosure, functionally equivalent methods and compositions within the scope of the present disclosure will be apparent to those skilled in the art from the above description. Such modifications and variations are intended to be included within the scope of the present disclosure and / or the scope of the appended claims. It is understood that the present disclosure is limited to specific methods, compounds, or compositions, which may of course vary. It is also to be understood that the terminology used herein is for the purpose of describing specific embodiments only, and is not intended to be limiting.

Claims

1. a) Retifanlimab at a concentration of about 10 mg / mL to about 100 mg / mL; b) Acetate; c) Sucrose; d) Polysorbate 80 (“PS80”); and e) Water A pharmaceutical composition comprising the same.

2. The acetate is a) Present at a concentration of about 5 mM to about 30 mM, and / or b) Contains sodium acetate, The pharmaceutical composition according to Claim 1.

3. The composition is: a) Contains about 5 mM to about 30 mM acetate, about 50 mg / mL to about 130 mg / mL sucrose, about 0.02 mg / mL to about 0.6 mg / mL PS80, and water, and the pH of the composition is about 4.0 to about 6.5; b) Contains about 7.5 mM to about 20 mM acetate, about 50 mg / mL to about 130 mg / mL sucrose, about 0.05 mg / mL to about 0.6 mg / mL PS80, and water, and the pH of the composition is about 4.0 to about 6.5; c) Contains about 9 mM to about 11 mM acetate, about 76 mg / mL to about 104 mg / mL sucrose, about 0.08 mg / mL to about 0.53 mg / mL PS80, and water, and the pH of the composition is about 4.5 to about 5.7; or d) Contains about 9 mM to about 11 mM acetate, about 80 mg / mL to about 100 mg / mL sucrose, about 0.08 mg / mL to about 0.15 mg / mL PS80, and water, and the pH of the composition is about 4.5 to about 5.7, the pharmaceutical composition according to Claim 1 or 2.

4. The retifanlimab is a) Present at a concentration of about 20 mg / mL to about 30 mg / mL, or b) Present at a concentration of about 25 mg / mL, The pharmaceutical composition according to any one of Claims 1 to 3.

5. The acetate is a) Contains glacial acetic acid at a concentration of about 0.05 mg / mL to about 0.35 mg / mL and sodium acetate trihydrate at a concentration of about 0.80 mg / mL to about 2.0 mg / mL, or b) Contains glacial acetic acid at a concentration of 0.18 mg / mL and sodium acetate trihydrate at a concentration of about 0.95 mg / mL, The pharmaceutical composition according to any one of Claims 1 to 4.

6. The sucrose is a) Present at a concentration of about 80 mg / mL to about 100 mg / mL, or b) Present at a concentration of about 90 mg / mL, The pharmaceutical composition according to any one of Claims 1 to 5.

7. The PS80 is a) Present at a concentration of about 0.08 mg / mL to about 0.15 mg / mL, or b) Present at a concentration of about 0.1 mg / mL, The pharmaceutical composition according to any one of claims 1 to 6.

8. (a) The pH of the composition is from about 4.5 to about 5.7, or (b) The pH of the composition is about 5.1, The pharmaceutical composition according to any one of claims 1 to 7.

9. The composition contains about 25 mg / mL of rituximab, about 0.18 mg / mL of glacial acetic acid, about 0.95 mg / mL of sodium acetate trihydrate, about 90 mg / mL of sucrose, about 0.1 mg / mL of PS80, and water, and the pH of the composition is from about 4.8 to about 5.

4. The pharmaceutical composition according to any one of claims 1 to 8.

10. The composition has a shelf life of at least about 18 months, about 24 months, about 36 months, about 48 months, or about 60 months at about 2°C to about 8°C. The pharmaceutical composition according to any one of claims 1 to 9.

11. The weight osmolality of the composition is about 200 to about 400 mOsm / kg·H ２ 2O, about 225 to about 400 mOsm / kg·H2O, about 250 to about 375 mOsm / kg·H2O, or about 260 to about 340 mOsm / kg·H2O, the pharmaceutical composition according to any one of claims 1 to 10.

12. The composition (a) maintains the monomer purity of the rituximab for at least about 3 months at 25°C or for at least about 18 months at about 2°C to about 8°C, and / or (b) maintains the heterogeneity profile of the rituximab for at least about 3 months at 25°C or for at least about 18 months at about 2°C to about 8°C. The pharmaceutical composition according to any one of claims 1 to 11.

13. The water is sterilized non-pyrogenic distilled water. The pharmaceutical composition according to any one of claims 1 to 12.

14. The composition is sterilized. The pharmaceutical composition according to any one of claims 1 to 13.

15. A container comprising the pharmaceutical composition according to any one of claims 1 to 14, wherein the container (a) contains about 10 mL of the pharmaceutical composition, and the about 10 mL of the pharmaceutical composition comprises: (i) about 250 mg of rituximab; (ii) about 1.8 mg of glacial acetic acid; (iii) about 9.5 mg of sodium acetate trihydrate; (iv) about 900 mg of sucrose; (v) about 1 mg of PS80; and (vi) water and the pH of the composition is from about 4.8 to about 5.

4. (b) contains about 15 mL of the pharmaceutical composition, and the about 15 mL of the pharmaceutical composition comprises: (i) about 375 mg of rituximab; (ii) about 2.7 mg of glacial acetic acid; (iii) about 14.25 mg of sodium acetate trihydrate; (iv) about 1350 mg of sucrose; (v) about 1.5 mg of PS80; and (vi) water and The pH of the composition is from about 4.8 to about 5.4, or (c) containing about 20 mL by volume of the pharmaceutical composition, the about 20 mL by volume of the pharmaceutical composition comprising: (i) about 500 mg of ritlefanlimab; (ii) about 3.6 mg of glacial acetic acid; (iii) about 19 mg of sodium acetate trihydrate; (iv) about 1800 mg of sucrose; (v) about 2 mg of PS80; and (vi) water and the pH of the composition is from about 4.8 to about 5.4, container.

16. A kit comprising the pharmaceutical composition according to any one of claims 1 to 14, or the container according to claim 15, and optionally further comprising instructions for administering the pharmaceutical composition to a subject in need thereof.

17. A container containing a pharmaceutical composition, the composition comprising: a) from about 21 mg / mL to about 29 mg / mL of ritlefanlimab, from about 0.16 mg / mL to about 0.20 mg / mL of glacial acetic acid, from about 0.86 mg / mL to about 1.1 mg / mL of sodium acetate trihydrate, from about 76 mg / mL to about 104 mg / mL of sucrose, from about 0.08 mg / mL to about 0.53 mg / mL of PS80, and water, wherein the pH of the composition is from about 4.5 to about 5.7; or b) from about 22.5 mg / mL to about 27.5 mg / mL of ritlefanlimab, from about 0.16 mg / mL to about 0.20 mg / mL of glacial acetic acid, from about 0.86 mg / mL to about 1.1 mg / mL of sodium acetate trihydrate, from about 76 mg / mL to about 104 mg / mL of sucrose, from about 0.08 mg / mL to about 0.53 mg / mL of PS80, and water, wherein the pH of the composition is from about 4.5 to about 5.7; or c) about 250 mg of ritlefanlimab, about 1.8 mg of glacial acetic acid, about 9.5 mg of sodium acetate trihydrate, about 900 mg of sucrose, about 1 mg of PS80, wherein the pH of the composition is from about 4.8 to about 5.4; or d) about 375 mg of ritlefanlimab, about 2.7 mg of glacial acetic acid, about 14.25 mg of sodium acetate trihydrate, about 1350 mg of sucrose, about 1.5 mg of PS80, wherein the pH of the composition is from about 4.8 to about 5.4; or e) about 500 mg of ritlefanlimab, about 3.6 mg of glacial acetic acid, about 19 mg of sodium acetate trihydrate, about 1800 mg of sucrose, about 2 mg of PS80, wherein the pH of the composition is from about 4.8 to about 5.4, a container Instructions for optionally administering the pharmaceutical composition to a subject in need thereof, and A kit comprising the same. **Claim 18** The composition according to claim 16 or 17, wherein the composition comprises about 25 mg / mL of retifanlimab, about 0.18 mg / mL of glacial acetic acid, about 0.95 mg / mL of sodium acetate trihydrate, about 90 mg / mL of sucrose, about 0.1 mg / mL of PS80, and water, and the pH of the composition is about 4.8 to about 5.

4. **Claim 19** The kit according to claim 16 or 17, wherein the composition comprises about 250 mg of retifanlimab, about 1.8 mg of glacial acetic acid, about 9.5 mg of sodium acetate trihydrate, about 900 mg of sucrose, and about 1 mg of PS80, and the pH of the composition is about 4.8 to about 5.

4. **Claim 20** The kit according to claim 16 or 17, wherein the composition comprises about 375 mg of retifanlimab, about 2.7 mg of glacial acetic acid, about 14.25 mg of sodium acetate trihydrate, about 1350 mg of sucrose, and about 1.5 mg of PS80, and the pH of the composition is about 4.8 to about 5.

4. **Claim 21** The kit according to claim 16 or 17, wherein the composition comprises about 500 mg of retifanlimab, about 3.6 mg of glacial acetic acid, about 19 mg of sodium acetate trihydrate, about 1800 mg of sucrose, and about 2 mg of PS80, and the pH of the composition is about 4.8 to about 5.

4. **Claim 22** The pharmaceutical composition according to any one of claims 1 to 15, the container according to claim 16, and the kit according to any one of claims 17 to 21, which are used for treating cancer in a subject in need of cancer treatment. **Claim 23** The use is as follows: a) Diluting the pharmaceutical composition in 0.9% sodium chloride in a container to obtain a dosing solution; b) Inverting the container to mix the diluted solution; and c) Attaching the container containing the dosing solution to a device for administration to the subject The pharmaceutical composition according to claim 22, comprising the steps. **Claim 24** The pharmaceutical composition according to claim 23, wherein the container is an IV bag containing 0.9% sodium chloride. **Claim 25** The use is as follows: a) Diluting the pharmaceutical composition in 5% dextrose in water (D5W) in a container to obtain a dosing solution; b) Inverting the container to mix the diluted solution; and c) attaching the container containing the dosing solution to a device for administration to the subject The pharmaceutical composition according to claim 22, comprising: **Claim 26** The pharmaceutical composition according to claim 25, wherein the container is an IV bag containing D5W. **Claim 27** The pharmaceutical composition according to any one of claims 22-26, wherein the dosing solution maintains the monomer purity of the retifanlimab at about 25°C for about 6 hours or at about 2°C to about 8°C for about 24 hours. **Claim 28** The pharmaceutical composition according to any one of claims 22-27, wherein the administration is by IV infusion over at least about 30 minutes. **Claim 29** Diluting the pharmaceutical composition to obtain a uniform dose of about 375 mg, the method according to any one of claims 44-48 or 55-57, or the pharmaceutical composition according to any one of claims 22-28. **Claim 30** The pharmaceutical composition according to any one of claims 22-29, wherein the dosing solution is administered once every two weeks, once every three weeks, or once every four weeks. **Claim 31** The pharmaceutical composition according to any one of claims 22-30, wherein the cancer expresses PD-L1. **Claim 32** The cancer is: adrenal cancer, AIDS-related cancer, alveolar soft part sarcoma, anal cancer, anal canal squamous cell carcinoma (SCAC), bladder cancer, bone cancer, brain and spinal cord cancer, breast cancer, HER2 ＋ breast cancer or triple-negative breast cancer (TNBC), carotid body tumor, cervical cancer, HPV-related cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, desmoplastic small round cell tumor, epithelioma, endometrial cancer, unselected endometrial cancer, MSI-high endometrial cancer, dMMR endometrial cancer, DNA polymerase ε (POLE) exonuclease domain mutant positive endometrial cancer, Ewing sarcoma, extraskeletal myxoid chondrosarcoma, gallbladder or bile duct cancer, cholangiocarcinoma, gastric cancer, esophagogastric junction (GEJ) cancer, gestational trophoblastic disease, germ cell tumor, glioma, glioblastoma, head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), hematologic malignancy, hepatocellular carcinoma, islet cell tumor, Kaposi sarcoma, kidney cancer, renal cell carcinoma (RCC), clear cell RCC, papillary RCC, and chromophobe RCC, leukemia, acute myeloid leukemia, liposarcoma / malignant lipomatous tumor, liver cancer, hepatocellular carcinoma (HCC), lymphoma, diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma (NHL), lung cancer, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), medulloblastoma, melanoma, uveal melanoma, meningioma, mesothelioma, mesothelioma of the pharynx, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumor, ovarian cancer, pancreatic cancer, papillary thyroid cancer, parathyroid tumor, pediatric cancer, peripheral nerve sheath tumor, pharyngeal cancer, pheochromocytoma, pituitary tumor, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), posterior uveal melanoma, renal metastatic cancer, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin cancer, Merkel cell carcinoma, small round blue cell tumor of childhood, neuroblastoma, rhabdomyosarcoma, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymic cancer, thymoma, thyroid cancer, urothelial cancer, and uterine cancer, and is selected from the group consisting of the pharmaceutical composition according to any one of claims 22 to 31. **Claim 33** The pharmaceutical composition according to claim 32, wherein the cancer is anal cancer, breast cancer, colorectal cancer, endometrial cancer, gastric cancer, GEJ cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, and urothelial cancer. **Claim 34** The pharmaceutical composition according to claim 32, wherein the cancer is SCAC. **Claim 35** The pharmaceutical composition according to claim 32, wherein the lung cancer is NSCLC. **Claim 36** The pharmaceutical composition according to claim 32, wherein the endometrial cancer is MSI-high endometrial cancer, dMMR endometrial cancer, or POLE exonuclease domain mutant positive endometrial cancer. **Claim 37** The pharmaceutical composition according to claim 32, wherein the skin cancer is melanoma or Merkel cell carcinoma. **Claim 38** The pharmaceutical composition according to claim 32, wherein the head and neck cancer is SCCHN. **Claim 39** The pharmaceutical composition according to claim 32, wherein the prostate cancer is mCRPC. **Claim 40** The pharmaceutical composition according to claim 32, wherein the kidney cancer is RCC or clear cell RCC. **Claim 41** The pharmaceutical composition according to claim 32, wherein the cancer is urothelial cancer. **Claim 42** The pharmaceutical composition according to any one of claims 22 to 41, wherein the subject is a human subject.

43. A kit comprising the pharmaceutical composition according to any one of claims 1 to 14 and a further therapeutic agent, and optionally further comprising instructions for administering the pharmaceutical composition to a subject in need thereof.

44. The kit according to claim 43, which is used for treating cancer in a subject in need of cancer treatment.

45. a) Retifanlimab at about 10 mg / mL to about 100 mg / mL; b) Acetate; c) Sucrose; d) Polysorbate 80 ("PS80"); e) Water; and f) A further therapeutic agent A pharmaceutical composition comprising.

46. (1) A pharmaceutical composition comprising the following, a) Retifanlimab at about 10 mg / mL to about 100 mg / mL; b) Acetate; c) Sucrose; d) Polysorbate 80 ("PS80"); and e) Water (2) A further therapeutic agent Combination of.

47. The pharmaceutical composition according to claim 45, or the combination according to claim 46, wherein the further therapeutic agent comprises a chemotherapeutic agent, a biologic agent, or a hormonal therapy agent.

48. The chemotherapeutic agent comprises an antimetabolite chemotherapeutic agent, a platinum-based chemotherapeutic agent, and / or a taxane-based chemotherapeutic agent, optionally comprising the platinum-based chemotherapeutic agent and the taxane-based chemotherapeutic agent, wherein the platinum-based chemotherapeutic agent is carboplatin and the taxane-based chemotherapeutic agent is paclitaxel. The pharmaceutical composition according to claim 47, or the combination according to claim 47.

49. The pharmaceutical composition according to any one of claims 45, 47, and 48, or the combination according to any one of claims 46 to 48, which is used for treating cancer in a subject in need of cancer treatment.

Images